0001731122-20-001140.txt : 20201112 0001731122-20-001140.hdr.sgml : 20201112 20201112172854 ACCESSION NUMBER: 0001731122-20-001140 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201112 DATE AS OF CHANGE: 20201112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Enochian Biosciences Inc CENTRAL INDEX KEY: 0001527728 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452259340 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38758 FILM NUMBER: 201308154 BUSINESS ADDRESS: STREET 1: CENTURY CITY MEDICAL PLAZA STREET 2: 2080 CENTURY CITY EAST CITY: SUITE 906 LOS ANGELES STATE: CA ZIP: 90067 BUSINESS PHONE: 45 39179840 MAIL ADDRESS: STREET 1: CENTURY CITY MEDICAL PLAZA STREET 2: 2080 CENTURY CITY EAST CITY: SUITE 906 LOS ANGELES STATE: CA ZIP: 90067 FORMER COMPANY: FORMER CONFORMED NAME: DanDrit Biotech USA, Inc. DATE OF NAME CHANGE: 20140214 FORMER COMPANY: FORMER CONFORMED NAME: Putnam Hills Corp. DATE OF NAME CHANGE: 20110810 10-Q 1 e2200_10-q.htm FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission file number 001-38758

Enochian Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		45-2259340
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

Enochian Biosciences, Inc.

2080 Century Park East, Suite 906

Los Angeles, CA 90067

+1(786) 888-1685

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		ENOB		The Nasdaq Stock Market LLC

As of November 12, 2020, the number of shares of the registrant’s common stock outstanding was 46,636,976.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES

- INDEX -

		Page
PART I – FINANCIAL INFORMATION:		1

Item 1.	Financial Statements (Unaudited):	1

	Condensed Consolidated Balance Sheets as of September 30, 2020 (Unaudited) and June 30, 2020	2

	Condensed Consolidated Statements of Operations for the Three Months September 30, 2020 and September 30, 2019 (Unaudited)	3

	Condensed Consolidated Statements of Other Comprehensive Loss for the Three Months Ended September 30, 2020 and September 30, 2019 (Unaudited)	4

	Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended September 30, 2020 and September 30, 2019 (Unaudited)	5

	Condensed Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2020 and September 30, 2019 (Unaudited)	6

	Notes to the Condensed Consolidated Financial Statements (Unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26

Item 4.	Controls and Procedures	26

PART II – OTHER INFORMATION:		27

Item 1.	Legal Proceedings	27

Item 1A.	Risk Factors	27

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27

Item 3.	Defaults Upon Senior Securities	27

Item 4.	Mine Safety Disclosures	27

Item 5.	Other Information	27

Item 6.	Exhibits	27

Signatures		28

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the instructions for Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, the financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.

The results for the period ended September 30, 2020 are not necessarily indicative of the results of operations for the full year. These financial statements and related footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Form 10-K for the fiscal year ended June 30, 2020, filed with the Securities and Exchange Commission on September 23, 2020.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30,			June 30,
	2020			2020
	(Unaudited)
ASSETS
Current Assets:
Cash	$	5,965,661		$	8,696,361
Other receivables					1,982
Prepaid expenses		99,872			242,866
Total Current Assets		6,065,533			8,941,209

Property and equipment, net		751,573			778,118

OTHER ASSETS
Definite life intangible assets, net		76,834			77,323
Indefinite life intangible assets		154,824,000			154,824,000
Goodwill		11,640,000			11,640,000
Deposits and other assets		137,550			137,550
Right of use assets		1,637,878			1,703,859
Total Other Assets		168,316,262			168,382,732

TOTAL ASSETS	$	175,133,368		$	178,102,059

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:
Accounts payable – trade	$	282,376		$	592,877
Accrued expenses		273,345			470,636
Current portion of operating lease liabilities		276,456			271,285
Total Current Liabilities		832,177			1,334,798

NON-CURRENT LIABILITIES
Contingent Consideration Liability		2,755,034			3,182,434
Leases liabilities, non-current		1,461,156			1,531,779
Convertible Notes Payable-LT		1,200,000			1,200,000
Notes payable - LT, net of discount		4,654,765			4,580,787

Total Liabilities	$	10,903,132			11,829,798

Commitments and Contingencies		—			—

STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding		—			—
Common stock, par value $0.0001, 100,000,000 shares authorized, 46,636,976 shares issued and outstanding at September 30, 2020; 46,497,409 shares issued and outstanding at June 30, 2020		4,664			4,650
Additional paid-in capital		230,823,367			230,497,225
Accumulated deficit		(66,584,768	)		(64,188,198	)
Accumulated other comprehensive loss		(13,027	)		(41,416	)
Total Stockholders’ Equity		164,230,236			166,272,261

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	175,133,368		$	178,102,059

See accompanying notes to the unaudited condensed consolidated financial statements.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED

CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

	For the Three Months
	Ended
	September 30,
	2020			2019
Revenues	$	—		$	—

Cost of Goods Sold	$	—		$	—

Gross profit (Loss)	$	—		$	—

Operating Expenses
General and administrative expenses		1,777,923			1,900,812
Research and development expenses		1,050,376			520,192
Depreciation and amortization		30,458			21,481

Total Operating Expense	$	2,858,757		$	2,442,485

LOSS FROM OPERATIONS	$	(2,858,757	)	$	(2,442,485	)

Other Income (Expense)
Change in fair value of contingent consideration		427,400			(1,942,000	)
Interest income (expense)		(92,313	)		—
Gain (loss) on currency transactions					286,755
Interest and other income		4,306			14,553
Total Other Income (Expense)		339,393			(1,640,692	)

Loss Before Income Taxes		(2,519,365	)		(4,083,177	)

Income Tax Benefit	$	122,794		$	—

NET LOSS	$	(2,396,570	)	$	(4,083,177	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.05	)	$	(0.09	)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED		46,605,118			46,241,315

See accompanying notes to the unaudited condensed consolidated financial statements

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS

(UNAUDITED)

	For the Three Months
	Ended
	September 30,
	2020			2019
Net Loss	$	(2,396,570	)	$	(4,083,177	)
Foreign Currency Translation, Adjustments		28,389			(278,656	)

Other Comprehensive Loss	$	(2,368,181	)	$	(4,361,833	)

See accompanying notes to the unaudited condensed consolidated financial statements.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

	# of Shares		Common Shares		Additional Paid-In Capital			Accumulated Deficit			Accumulated Other Comprehensive Income			Total
July 1, 2020		46,497,409	$	4,650	$	230,497,225		$	(64,188,198	)	$	(41,416	)	$	166,272,261
Stock-based compensation						326,156									326,156
Issuance of commitment shares		139,567		14		(14	)		—			—			—
Net Loss		—		—		—			(2,396,570	)		—			(2,396,570	)
Foreign Currency Translation Adjustment		—		—		—			—			28,389			28,389
September 30, 2020		46,636,976	$	4,664	$	230,823,367		$	(66,584,768	)	$	(13,027	)	$	164,230,236

July 1, 2019		45,273,924	$	4,527	$	225,765,432		$	(52,771,840	)	$	101,818		$	173,099,937

Stock issued pursuant to warrants exercised		500,000		50		999,950			—			—			1,000,000
Contingent Share issued pursuant to Acquisition Agreement		500,000		50		2,209,950			—			—			2,210,000
Stock-based compensation						234,010			—			—			234,010
Net Loss		—		—		—			(4,083,177	)		—			(4,083,177	)
Other Comprehensive Loss
Foreign Currency Translation Adjustment		—		—		—			—			(278,656	)		(278,656	)
September 30, 2019		46,273,924	$	4,627	$	229,209,342		$	(56,855,017	)	$	(176,838	)	$	172,182,114

See accompanying notes to the unaudited condensed consolidated financial statements.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

	For the Three Months Ended
	September 30,
	2020			2019
NET LOSS	$	(2,396,570	)	$	(4,083,177	)

ADJUSTMENT TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation and amortization		30,458			21,481
Change in contingent consideration liability		(427,400	)		1,942,000
Stock Based Compensation Expense		326,156			234,010
ROU assets		65,981			68,866
Amortization of Discount of Notes Payable		73,978			—
CHANGES IN ASSETS AND LIABILITIES:
Other Receivables		1,982			6,098
Prepaid Expenses/Deposits		142,994			135,793
Accounts Payable		(310,501	)		71,022
Accrued Expenses		(197,291	)		(136,424	)
Operating Lease Liabilities		(65,452	)		(60,256	)
NET CASH USED IN OPERATING ACTIVITIES	$	(2,755,665	)	$	(1,800,587	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		—			(68,616	)
NET CASH USED IN INVESTING ACTIVITIES	$	—		$	(68,616	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants		—			1,000,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	$	—		$	1,000,000

(Loss) on Currency Translation	$	24,965		$	(274,769	)

NET CHANGE IN CASH	$	(2,730,700	)		(1,143,972	)

CASH, BEGINNING OF PERIOD	$	8,696,361		$	12,282,224

CASH, END OF PERIOD	$	5,965,661		$	11,138,252

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the quarter end for:
Interest	$	42,365			—
Income Taxes	$	37			—

Non-cash operating, investing and financing Activities:
Contingent Shares issued in connection with Acquisition Agreement	$	—		$	2,210,000

See accompanying notes to the unaudited condensed consolidated financial statements.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARY

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business– Enochian BioSciences Inc., (“Enochian”, or “Registrant”, and together with its subsidiaries, the “Company”, “we” or “us”) is a pre-clinical stage biotechnology company committed to using our genetically modified cellular and immune-therapy technologies to prevent or potentially cure HIV, Hepatitis B (HBV), and to provide potentially life-long cancer remission of some of the deadliest cancers.

Basis of Presentation- The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and follows the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2020 and 2019 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s June 30, 2020 audited financial statements. The results of operations for the periods ended September 30, 2020 and 2019 are not necessarily indicative of the operating results for the full year.

Consolidation - For the three months ended September 30, 2020 and 2019, the consolidated financial statements include the accounts and operations of the Registrant, and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.

Reclassification–Certain amounts in the prior period financial statements have been reclassified to conform to the current presentation. For the three months ended September 30, 2019, we reclassified consulting expense of $31,850, to general and administrative expenses.

Accounting Estimates - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, and fair value of equity instruments issued.

COVID-19- During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (COVID-19). The pandemic has significantly affected the economic conditions in the U.S. A number of states, counties and municipalities issued orders requiring persons who were not engaged in essential activities and businesses to remain at home. On March 27, 2020, the US enacted the Coronavirus Aid, Relief and Economic Security Aid (“CARES Act”) to help stimulate an economic recovery; however, there are no reliable estimates of how long the pandemic will last or how many people are likely to be affected by it. No one knows what over-all effects the COVID-19 pandemic will have on economic conditions during the remainder of the fiscal year.

Our senior management team is monitoring COVID-19’s impact daily and will continue to adjust our operations as necessary. However, the impact of this event on the Company’s results of operations, financial position, and liquidity or capital resources cannot be reasonably estimated at this time.

Functional Currency & Foreign currency translation - The functional currency of Enochian Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ended September 30, 2020, and June 30, 2020, and September 30, 2019. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Cash and Cash Equivalents —The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held in financial institutions in Denmark and in the United States in excess of federally insured States amounts at September 30, 2020 and June 30, 2020 of $5,965,661 and $8,696,361, respectively.

Property and Equipment — Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets, which range from four to ten years (See Note 3).

Intangible Assets - The Company has both Definite and Indefinite life intangible assets.

Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.

Indefinite life intangible assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. License agreement costs represent the Fair Value of the license agreement on the date acquired and are tested annually for impairment. The fair value analysis performed on the license agreements, and the fair value analysis performed on goodwill supported that both indefinite life intangible assets are not impaired as of June 30, 2020, and no impairment is deemed necessary as of September 30, 2020. (See Note 4)

Goodwill —Goodwill is not amortized but is evaluated for impairment annually as of June 30^th or whenever events or changes in circumstances indicate the carrying value may not be recoverable.

We test for goodwill impairment at the reporting unit level, which is one level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of the reporting unit and is based on discounted cash flows or relative market-based approaches. If the fair value exceeds carrying value, then it is concluded that no goodwill impairment has occurred. If the carrying value of the reporting unit exceeds its fair value, a second step is required to measure possible goodwill impairment loss. The second step includes hypothetically valuing the tangible and intangible assets and liabilities of the reporting unit as if the reporting unit had been acquired in a business combination. Then, the implied fair value of the reporting unit’s goodwill is compared to the carrying value of that goodwill. If the carrying value of the reporting unit’s goodwill exceeds the implied fair value of the goodwill, we recognize an impairment loss in an amount equal to the excess, not to exceed the carrying value.

The carrying value of goodwill at September 30, 2020, was $11,640,000. We do not believe there is a reasonable likelihood that there will be a material change in the future estimates or assumptions we use to test for impairment losses on goodwill. However, if actual results are not consistent with our estimates or assumptions, we may be exposed to an impairment charge that could be material.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Impairment of Long-Lived Assets — Long-lived assets, such as property, plant, and equipment, patents and licenses are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.

Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.

Leases — In accordance with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information available at the commencement date in determining the present value of the future payments.

Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statement of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited condensed consolidated statements of operations.

The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred. (See Note 5).

Research and Development Expenses — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of the HIV, HBV, and Cancer therapies and technologies for use in the prevention, treatment, amelioration of and/or therapy for HIV, HBV, and Cancer. Research and development expenses for the three months ended September 30, 2020 and 2019, amounted to $1,050,376, and $520,192, respectively.

Income Taxes — The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach for accounting for income taxes. During the quarter ended September 30, 2020, the Company’s Danish subsidiary received a payment for an R&D tax credit owed under Danish statutory tax laws in the amount of $122,831.

Loss Per Share — The Company calculates earnings/(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of shares of Common Stock, par value 0.0001 per share (“Common Stock”) outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive shares of Common Stock. Potential shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised. Because of the net loss for the three ended September 30, 2020 and 2019, the dilutive shares for both periods were excluded from the Diluted EPS calculation as the effect of these potential shares of Common Stock is anti-dilutive. The Company had 4,115,883 and 3,441,375 potential shares of Common Stock excluded from the Diluted EPS calculation as of September 30, 2020 and September 30, 2019.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

●

Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company adopted ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements, which amends certain disclosures requirements over fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on July 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (See Note 2-Fair Value of Financial Instruments for more information about the Company’s fair value classifications.)

Stock Options and Restricted Share Units - The Company has granted stock options, restricted share units (“RSU’s) and warrants. The Company accounts for options in accordance with the provisions of FASB ASC Topic 718, Compensation - Stock Compensation. Stock based compensation costs for the vesting of options and RSU’s granted to officers, board members, employees and consultants for the three months ended September 30, 2020 and 2019 were $326,156 and $234,010, respectively.

Stock-Based Compensation -The Company records stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued and are recognized over the employees required service period, which is generally the vesting period. No shares were issued for services for the three months ended September 30, 2020 and 2019.

Recent Adopted Accounting Pronouncements

The Company adopted ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements, as of July 1, 2020 (Note 2).

Other recent accounting pronouncements issued by the FASB do not or are not believed by management to have a material impact on the Company’s present or future financial statements.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 — FAIR VALUE MEASUREMENT — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

●

Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The were no Level 1, 2 or 3 assets, nor and Level 1 or 2 liabilities as of September 30, 2020.

Level 3 liabilities held as of September 30, 2020 consisted of a contingent consideration liability related to the February 16, 2018 acquisition of Enochian BioPharma (the “Acquisition”). As consideration for the Acquisition, the stockholders of Enochian Biopharma received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive Contingent Shares pro rata upon the exercise of warrants, which were outstanding at closing. The contingent consideration liability was recorded at fair value of $21,516,000 at the time of acquisition and is subsequently remeasured to fair value at each reporting period. At September 30, 2020, 1,438,122 Contingent Shares are issuable in connection with the Acquisition of Enochian Biopharma.

The fair value of the contingent consideration liability is estimated using an option-pricing model. The key inputs to the model are all contractual or observable with the exception being volatility, which is computed, based on the Company’s underlying stock. The key inputs to valuing the contingent consideration liability on the date of acquisition and as of September 30, 2020, include the Company’s stock price on the valuation date of $3.58; the exercise price of the warrants of $1.30, the risk-free rate of .13% the expected volatility of the Company’s Common Stock of 99.3%, the digital call rate 54%, and the 1,438,122 of contingent shares remaining at the end of the period. Fair Value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value.

Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.

The following table sets forth the Level 3 liability at September 30, 2020, which is recorded on the balance sheet at fair value on a recurring basis. As required, these are classified based on the lowest level of input that is significant to the fair value measurement:

	Fair Value Measurements at Reporting Date Using
	Quoted Prices in Active Markets for Identical Assets Inputs		Significant Other Observable Inputs		Significant Other Unobservable
	(Level 1)		(Level 2)		(Level 3)
Contingent Consideration Liability		—		—	$	2,755,034
The roll forward of the contingent consideration liability is as follows:
Balance June 30, 2020		—		—	$	3,182,434
Contingent Shares issued pursuant to the Acquisition Agreement		—		—	$	—
Fair value adjustment		—		—	$	(427,400	)
Balance September 30, 2020		—		—	$	2,755,034

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3 — PROPERTY AND EQUIPMENT

	Useful Life	September 30, 2020			June 30, 2020
Lab Equipment and Instruments	4-7	$	534,527		$	534,527
Leasehold Improvements	10	$	224,629			224,629
Furniture Fixtures and Equipment	4-7	$	171,975		$	171,975
Total		$	931,131		$	931,131
Less Accumulated Depreciation		$	(179,558	)	$	(153,013	)
Net Property and Equipment		$	751,573		$	778,118

During the three months ended September 30, 2020, and 2019, respectively, the Company had depreciation expense of $26,545, and $21,481, respectively.

NOTE 4 —INTANGIBLE ASSETS

At September 30, 2020 and June 30, 2020, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company’s products and processes of $76,834 and $77,323, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense for the three months ended September 30, 2020 and 2019 was $3,913 and zero, respectively.

At September 30, 2020 and 2019, indefinite life intangibles assets consisted of a licenses agreements classified as In-Process Research and Development (“IPR&D”) intangible assets, which are not amortizable until the intangible asset provides economic benefit, and goodwill.

At September 30, 2020 and June 30, 2020, definite and indefinite-life intangible assets consisted of the following:

	Useful Life	June 30, 2020			Period Change			Effect of Currency Translation			September 30, 2020
Definite Life Intangible Assets
Patents	20 Years	$	299,175		$				13,247			312,422
Less Accumulated Amortization		$	(221,852	)	$	(3, 913	)		(9,823	)		(235,588	)
Net Definite-Life Intangible Assets		$	77,323		$	(3,913	)		3,424			76,834

Indefinite Life Intangible Assets
License Agreement		$	154,824,000								$	154,824,000
Goodwill		$	11,640,000								$	11,640,000
Total Indefinite Life Intangible Assets		$	166,464,000								$	166,464,000

Year ending September 30,
2021	$	11,241
2022	$	15,154
2023	$	15,154
2024	$	15,154
2025	$	15,154
Thereafter	$	4,977
Total	$	76,834

During February 2018, the Company acquired a License Agreement (as licensee) to the HIV therapy being developed as ENOB-HV-01 which consists of a perpetual, fully paid-up, royalty-free, sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. Because the HIV License Agreement is considered, an IPR&D intangible asset it is classified as an indefinite life asset that is tested annually for impairment.

Impairment – Following the fourth quarter of each year, management performs its annual test of impairment of intangible assets by performing a quantitative assessment and determines if it is more than likely than not that, the fair value of the asset is greater than or equal to the carrying value of the asset. The results of the quantitative assessment supported Management’s conclusion that an impairment adjustment was not required as of June 30, 2020.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5 — LEASES

Operating Leases — On November 13, 2017, Enochian entered into a Lease Agreement for a term of five years and two months from November 1, 2017 (the “Term”) with Plaza Medical Office Building, LLC, a California limited liability company (the “Landlord”), as landlord, pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increases by 3% each year, and ranges from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The Company received $70,800 in tenant improvement allowance in the form of free rent applied over 10 months in equal installments beginning in January of 2018.

On June 19, 2018, the Registrant entered into a Lease Agreement for a term of ten years from September 1, 2018 with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Registrant entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the remainder of the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050. The Company was entitled to $148,168 in contributions toward tenant improvements.

The Company identified and assessed the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities:

Expected lease term — The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably certain that the Company would exercise such options. The Company’s leases have remaining lease terms between 27 months and 83 months. As of September 30, 2020, the weighted-average remaining term is 6.24 years.

Incremental borrowing rate — The Company’s lease agreements do not provide an implicit rate. As the Company does not have any external borrowings for comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury Yield Curve rate that corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if borrowing on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. As of September 30, 2020, the weighted-average discount rate is 3.99%.

Lease and non-lease components — In certain cases the Company is required to pay for certain additional charges for operating costs, including insurance, maintenance, taxes, and other costs incurred, which are billed based on both usage and as a percentage of the Company’s share of total square footage. The Company determined that these costs are non-lease components and they are not included in the calculation of the lease liabilities because they are variable. Payments for these variable, non-lease components are considered variable lease costs and are recognized in the period in which the costs are incurred.

For the three months ended September 30, 2020, and September 30, 2019, lease expense charged to general and administrative expenses amounted to $89,684 and $101,521, respectively.

Below are the lease commitments for the next 5 years and thereafter:

Year Ending June 30^th	Lease Expense
2021	$	255,137
2022	$	348,495
2023	$	298,305
2024	$	246,004
2025	$	253,384
Thereafter	$	574,821
Less imputed interest		(238,535	)
Total	$	1,737,611

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 — NOTES PAYABLE

Convertible Notes Payable

On February 6, 2020, the Company issued two Convertible Notes (the “Convertible Notes”) to an existing stockholder of the Company each with a face value amount of $600,000, convertible into shares of the Company’s Common Stock. The outstanding principal amount of the Convertible Notes is due and payable on February 6, 2023. Interest on the Convertible Notes commenced accruing on the date of issuance at six percent (6%) per annum, computed on the basis of twelve 30-day months, and is compounded monthly on the final day of each calendar month based upon the Principal and all accrued and unpaid Interest outstanding as of such compound date. The interest is payable in cash on a semi-annual basis.

The holder of the Convertible Notes has the right at any time prior to the date that is twelve months from issuance to convert all or any part of the outstanding and unpaid Principal and all unpaid Interest into shares of the Company’s Common Stock. The conversion price is equal to $12.00 per share of Common Stock. The Company evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded conversion feature that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily convertible into cash. All proceeds received from the issuance have been recognized as a liability on the balance sheet. The Convertible Notes balance as of September 30, 2020 and June 30, 2020, was $1,200,000.

Note Payable

On March 30, 2020 (the “Issuance Date”), the Company issued a Promissory Note in the principal amount of $5,000,000 (the “Unsecured Note”) to Paseco APS, a Danish limited company and an existing stockholder of the Company. The principal amount of the Note will be payable on November 30, 2021 (the “Maturity Date”) and bears interest at a fixed rate of 6% per annum, computed based on the number of days between the Issuance Date and the Maturity Date, which was prepaid by the Company in full on the Issuance Date through the issuance of 188,485 shares of the Company’s Common Stock based on the closing market price on that date for a total value of $501,370. The Company evaluated the Unsecured Note and PIK interest in accordance with ASC 470-Debt and ASC 835-Interest, respectively. Pursuant to ASC 470-20, proceeds received from the issuance are to be recognized at their relative fair value, thus the liability is shown net of the corresponding discount of $493,192, which is the relative fair value of the shares issued for the PIK interest on the closing date using the effective interest method. The discount will be accreted over the life of the Unsecured Note. The Note Payable balance, net of discount at September 30, 2020 is $4,654,765.

For the three months ended September 30, 2020, the Company recorded accrued interest and interest expense in the amount of $6,000, and $92,313, respectively. The interest expense includes $73,978 related to the amortization of the discount related to the Unsecured Note. These amounts are reflected in accrued expenses and general and administrative expenses.

NOTE 7 — STOCKHOLDERS’ EQUITY

Preferred Stock — The Company has 10,000,000 authorized shares of Preferred Stock, par value $0.0001 per share. At September 30, 2020, and June 30, 2020, there were zero shares issued and outstanding.

Common Stock — The Company has 100,000,000 authorized shares of Common Stock, par value $0.0001 per share. At September 30, 2020, and June 30, 2020, there were 46,636,976 and 46,497,409 shares issued and outstanding, respectively.

Voting — Holders of Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors.

Dividends — Holders of Common Stock are entitled to receive ratably such dividends as the Board from time to time may declare out of funds legally available.

Liquidation Rights — In the event of any liquidation, dissolution or winding-up of affairs of the Company, after payment of all of our debts and liabilities, the holders of Common Stock will be entitled to share ratably in the distribution of any of our remaining assets.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 — STOCKHOLDERS’ EQUITY (Continued)

Purchase Agreement with Lincoln Park Capital

On July 8, 2020, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $20,000,000 of shares of our Common Stock from time to time from August 1, 2023.

Under the Purchase Agreement, we may direct Lincoln Park, at our sole discretion subject to certain conditions, to purchase up to 200,000 shares of Common Stock on any business day (a “Regular Purchase”). The amount of a Regular Purchase may be increased under certain circumstances up to 125,000 shares of Common Stock, provided that Lincoln Park’s committed obligation for Regular Purchases on any business day shall not exceed $1,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase price of shares of Common Stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the Purchase Agreement.

Our sale of shares of Common Stock to Lincoln Park subsequent to the Amendment Date is limited to 12,016,457 shares of Common Stock, representing 19.99% of the shares of the Common Stock outstanding on the Amendment Date unless (i) stockholder approval is obtained, (ii) the average price of all applicable sales to Lincoln Park under the Purchase Agreement equals or exceeds the lower of (A) the closing price of the Common Stock on the Nasdaq Capital Market immediately preceding the date of the Purchase Agreement or (B) the average of the closing prices on the Nasdaq Capital Market for the five Business Days immediately preceding the date of the Purchase Agreement or (ii) to the extent it would cause Lincoln Park to beneficially own more than 9.99% of the Company’s outstanding shares of Common Stock at any given time.

In consideration for entering into the Purchase Agreement, we issued 139,567 shares of Common Stock to Lincoln Park as a commitment fee on July 21, 2020.

During the three months ended September 30, 2020, we did not sell any shares of Common Stock to Lincoln Park under the Purchase Agreement.

Common Stock Issuances —

As of September 30, 2020, there were no other Common Stock issuances outside of the 139,567 shares of Common Stock issued to Lincoln Park as a commitment fee.

On July 3, 2019, the Registrant issued 500,000 shares of Common Stock valued at the price of $2.00 strike price per share pursuant to the exercise of vested options for total proceeds of $1.0 million.

On July 3, 2019, the Registrant issued 500,000 shares of Common Stock valued at the price of $4.42 per share in connection with the acquisition of Enochian Biopharma. This non-cash transaction impacted shareholders’ equity in the amount of $2.2 million.

Acquisition of Enochian Biopharma / Contingently issuable shares — On February 16, 2018, the Acquisition was completed when the subsidiary merged with and into Enochian Biopharma, with Enochian Biopharma as the surviving corporation. As consideration for the Acquisition, the stockholders of Enochian Biopharma received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive Contingent Shares pro rata upon the exercise or conversion of warrants, which were outstanding at closing. At September 30, 2020, 1,438,122 Contingent Shares are issuable in connection with the Acquisition of Enochian Biopharma.

Acquisition of Enochian Denmark — At September 30, 2020 and June 30, 2020, the Company maintained a reserve of 77,249 and 82,237 shares of Common Stock of the Registrant held in escrow according to Danish law (the “Escrow Shares”), respectively, all of which are reflected as issued and outstanding in the accompanying financial statements. The Escrow Shares are reserved to acquire the shares of Enochian Denmark held by non-consenting shareholders of Enochian Denmark on both September 30, 2020 and June 30, 2020, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark. There have been 107,804 shares of Common Stock issued to non-consenting shareholders of Enochian Denmark as of September 30, 2020. During the three months ended September 30, 2020, the Company issued 4,988 shares of Common Stock to such non-consenting shareholders of Enochian Denmark, respectively. There is no impact on outstanding shares as these shares are reflected as issued and outstanding.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 — STOCKHOLDERS’ EQUITY (Continued)

Recognition of Options

The Company recognizes compensation costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:

		Enochian Biosciences Inc.
Expected term (in years)		5.5
Volatility		79.92%-80.03%
Risk free interest rate		0.26%-.34%
Dividend yield		0%

The Company recognized stock-based compensation expense related to the options of $316,950 and $226,266 for the three months ended September 30, 2020 and year ended 2019, respectively. At September 30, 2020, the Company had approximately $836,754 of unrecognized compensation cost related to non-vested options.

Plan Options

On February 6, 2014, the Board adopted the Company’s 2014 Equity Incentive Plan (the “Plan”), and the Company had reserved 1,206,000 shares of Common Stock for issuance in accordance with the terms of the Plan.

On October 30, 2019, the Board approved and on October 31, 2019, the Company’s shareholders adopted the Enochian’s 2019 Equity Incentive Plan (the “2019 Plan”), which replaced the 2014 Plan. The 2019 Plan authorized options to be awarded to not exceed the sum of (1) 6,000,000 new shares of Common Stock, and (2) the number of shares of Common Stock available for the grant of awards as of the effective date under the 2014 Plan that, after the effective date of the 2019 Plan, expires, or is terminated, surrendered, or forfeited for any reason without issuance of shares. The remaining shares of Common Stock available for grant related to the 2014 Plan was of 655,769 as of the effective date, this amount along with the new 6,000,000 shares totals 6,655,769 shares of Common Stock available to grant immediately after the effective date of the 2019 Plan.

For the three months ended September 30, 2020, the Company granted annual options to purchase 24,196 shares of Common Stock to members of the Board of Directors and Scientific Advisory Board with a one-year vesting period. Options will be exercisable at the market price of the Company’s Common Stock on the date of the grant.

For the three months ended September 30, 2019, the Company granted annual options of 13,470 to members of the Board of Directors and Scientific Advisory Board with a one-year vesting period pursuant to their contracts, and granted 20,000 fully vested options to senior employees in pursuant to the 2014 Plan. Options will be exercisable at the market price of the Companys common stock on the date of the grant.

To date the Company has granted options under the 2019 Plan (“Plan Options”) to purchase 1,129,638 shares of Common Stock.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 — STOCKHOLDERS’ EQUITY (Continued)

A summary of the status of the Plan Options and Grant Warrants outstanding at September 30, 2020 is presented below:

Options Outstanding							Options Exercisable
	Exercise Prices		Number Outstanding		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price
	$	2.69		55,762		9.44	$	2.69		—		—	$	—
	$	3.26		23,006		9.42	$	3.26		—		—	$	—
	$	3.84		11,719		9.84	$	3.84		—		—	$	—
	$	3.85		5,195		9.84	$	3.85		—		—	$	—
	$	3.95		5,063		7.84	$	3.95		5,063		7.84	$	3.95
	$	4.12		7,282		9.80	$	4.12		—		—	$	—
	$	4.63		10,000		8.90	$	4.63		10,000		8.90	$	4.63
	$	4.80		50,749		9.25	$	4.80		—		—	$	—
	$	4.85		4,124		8.90	$	5.00		4,124		8.90	$	5.00
	$	4.90		9,183		8.86	$	4.90		9,183		8.86	$	4.90
	$	5.00		6,000		8.90	$	5.00		6000		—	$	5.00
	$	5.74		15,679		7.97	$	5.74		15,679		7.97	$	5.74
	$	5.80		7,759		8.03	$	5.80		7,759		8.03	$	5.80
	$	6.15		60,000		8.69	$	6.15		20,000		8.69	$	6.15
	$	6.25		24,001		8.44	$	6.25		24,001		8.44	$	6.25
	$	6.50		300,000		8.15	$	6.50		300,000		8.15	$	6.50
	$	6.95		4,317		8.53	$	6.95		4,317		8.53	$	6.95
	$	7.10		10,563		8.42	$	7.10		10,563		8.42	$	7.10
	$	8.00		519,235		9.42	$	8.00		55,695		7.60	$	8.00
Total	$	—		1,129,638		8.96	$	6.72		472,385		8.17	$	6.50

A summary of the status of the Plan Options at September 30, 2020 and changes since July 1, 2020 are presented below:

			Weighted Average		Average		Weighted Average
	Shares		Exercise Price		Remaining Life		Intrinsic Value

Outstanding at beginning of period		1,105,442	$	6.78		9.19	$	107,931
Granted		24,196	$	3.93		10.0		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
Outstanding at end of period		1,129,638	$	6.72		8.96	$	56,990
Vested and expected to vest								-
Exercisable end of period		472,385	$	6.50		8.17	$	-

At September 30, 2020, the Company had 472,385 exercisable Plan Options. The total intrinsic value of options at September 30, 2020 is zero. Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) at September 30, 2020 (for outstanding options), less the applicable exercise price.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 — STOCKHOLDERS’ EQUITY (Continued)

Common Stock Purchase Warrants

A summary of the shares of Common Stock, which can be purchased related to the underlying the warrants outstanding for the three-month period as of September 30, 2020, is presented below:

			Weighted Average		Weighted Average
	Shares		Exercise Price		Remaining Life

Outstanding at beginning of period		1,438,122	$	1.42		1.74
Granted
Exercised		-		-		-
Cancelled/Expired		-		-		-
Outstanding at end of period		1,438,122	$	1.42		1.74
Exercisable end of period		1,438,122	$	1.42		1.74

		Equivalent Shares		Underlying Warrants		Outstanding		Equivalent Shares Exercisable
Exercise Prices		Equivalent Shares		Weight Average Remaining Contractual Life (years)		Weight Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	1.30		1,413,122		1.76	$	1.30		1,413,122	$	1.30
$	8.00		25,000		.37	$	8.00		25,000	$	8.00

Total			1,438,122		1.74	$	1.42		1,438,122	$	1.42

The exercise price of certain warrants and the number of shares underlying the warrants are subject to adjustment for stock dividends, subdivisions of the outstanding shares of Common Stock and combinations of the outstanding shares of Common Stock. For so long as the warrants remain outstanding, we are required to keep reserved from our authorized and unissued shares of Common Stock a sufficient number of shares to provide for the issuance of the shares underlying the warrants.

Restricted Stock Units (RSUs)

The Company recognized stock-based compensation expense related to the RSUs of $9,206 and $7,744 for the three months ended September 30, 2020 and 2019, respectively

A summary of the status of Restricted Stock Units outstanding at September 30, 2020 is presented below:

			Weighted Average		Weighted Average		Weighted Average
	Shares		Issuance Price		Remaining Life		Intrinsic Value

Outstanding at beginning of period		10,000	$	6.15		.77	$	—
Granted			$				$	—
Exercised			$
Cancelled/Expired			$				$	—
Outstanding at end of period		10,000	$	6.15		.77	$	—
Exercisable end of period		—	$	—		—	$	—

		Restricted Stock Units Outstanding
Grant Price		Stock Units		Weight Average Remaining Contractual Life (years)		Weight Average Issuance Price
	6.15		10,000		.77	$	6.15
Total			10,000		.77	$	6.15

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 — COMMITMENTS AND CONTINGENCIES

Consulting Agreements –

On July 9, 2018, the Company entered into a consulting agreement with G-Tech Bio, LLC, a California limited liability company (“G-Tech”) to assist the Company with the development of the gene therapy and cell therapy modalities for the prevention, treatment, amelioration of HIV in humans, and with the development of a genetically enhanced Dendritic Cell for use as a wide spectrum platform for various diseases (including but not limited to cancers and infectious diseases) (the “G-Tech Agreement”). G-Tech was entitled to consulting fees for 20 months, with a monthly consulting fee of not greater than $130,000 per month. Upon the completion of the 20 months, the monthly consulting fee of $25,000 continued for scientific consulting and knowledge transfer on existing HIV experiments, and will continue until the services are no longer rendered or the agreement is terminated. G-Tech is controlled by certain members of Weird Science. For the three months ended September 30, 2020 and 2019, $50,000 and $375,000 was charged to research and development expenses in our Condensed Consolidated Statements of Operations related to this consulting agreement, respectively.

On January 31, 2020, the Company entered into a Statement of Work & License Agreement (the “HBV License Agreement”) by and among the Company, G Tech Bio, LLC, a California limited liability company (“G Tech”), and G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute (“SRI”), whereby the Company acquired a perpetual, sublicensable, exclusive license (the “HBV License”) for a treatment under development (the “Treatment”) aimed to treat Hepatitis B Virus (HBV) infections in accordance with its agreement in principle with G-Tech and SRI.

The HBV License Agreement states that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Treatment over a 24 month period, and provides for an up-front payment of $1.2 million within 7 days of January 31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides for cooperation related to the development of intellectual property related to the Treatment and for a 2% royalty to G Tech on any net sales that may occur under the HBV License. On February 6, 2020, the Company paid the $1.2 million aforementioned.

The cash funding for research costs and equipment pursuant to the HBV License Agreement consist of monthly payments amounting to $144,500 that cover scientific staffing resources to complete the project as well as periodic payments for materials and equipment needed to complete the project. During the three months ended September 30, 2020, the Company paid $433,500 for scientific staffing resources and $400,000 for mouse studies conducted by a collaborating partner.

The HBV License Agreement contains customary representations, warranties and covenants of the parties with respect to the development of the Treatment and the HBV License. G Tech and SRI are each controlled by certain members of Weird Science, LLC, a shareholder of the Company.

Shares held for non-consenting shareholders – The 77,249 remaining shares of Common Stock have been reflected as issued and outstanding in the accompanying financial statements. There were 4,988 shares of Common Stock issued to such non-consent shareholders during the three months ended September 30, 2020. (See Note 7)

Employment and Service Agreements - The Company has an agreement with the Executive Vice-Chair, where he fulfills the duties as prescribed by the Company’s bylaws and receives annual compensation in the amount of $430,000, plus 300,000 options that vested immediately. Dr. Dybul was given a one-time grant of options to purchase 450,000 shares of Common Stock at a strike price of $8.00 per share on June 11, 2020. The Company executed a consulting agreement for services for a Senior Medical Advisor of $210,000 on a part-time basis. The Company maintains employment agreements with other staff in the ordinary course of business.

Contingencies – From time to time, the Company is involved in routine legal and administrative proceedings and claims of various types. While any proceedings or claim contains an element of uncertainty, management does not expect a material impact on our results of operations or financial position.

ENOCHIAN BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 9 — RELATED PARTY TRANSACTIONS

On July 9, 2018, the Company entered into a consulting agreement with G-Tech to assist the Company with the development of the gene therapy and autologous and allogenic cell therapy modalities for the prevention, treatment, amelioration of HIV in humans, and with the development of a genetically enhanced Allogenic Dendritic Cell for use as a wide spectrum platform for various diseases (including but not limited to cancers and infectious diseases). (See Note 8)

On January 31, 2020, the Company entered into the HBV License Agreement by and among the Company, G Tech and SRI, whereby the Company acquired the HBV License for the Treatment. (See Note 8)

NOTE 10 — SUBSEQUENT EVENTS

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report. There have been no subsequent events of a significant and reportable nature as of November 12, 2020.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statement Notice

Certain statements made in this Quarterly Report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Enochian Biosciences, Inc. formerly DanDrit Biotech USA, Inc. (“Enochian”, and together with its subsidiaries, the “Company”, “we” or “us”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Our actual future results and trends may differ materially depending on a variety of factors, including, but not limited to, the risks and uncertainties discussed under “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The Company’s plans and objectives are based, in part, on assumptions involving the continued expansion of the business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance the forward-looking statements included in this Quarterly Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

Our Business

We are a pre-clinical stage biotechnology company committed to using our genetically modified cellular and immune-therapy technologies to prevent or potentially cure HIV, HBV and to potentially provide life-long cancer remission of some of the deadliest cancers. We do this by genetically modifying, or re-engineering, different types of cells, depending on the therapeutic area and then injecting or reinfusing the re-engineered cells back into the patient to provide treatment. In some of our interventions, immunotherapy is used.

To date, our operations have been funded by sales of our securities and the issuance of debt. Sales revenue will not support our current operations, and we expect this to be the case until our therapies or products are approved for marketing in the United States and Europe. Even if we are successful in having our therapies or products approved for sale in the United States and Europe, we cannot guarantee that a market for the product will develop. We may never be profitable.

Human Immunodeficiency Virus, or HIV, and Acquired Immunodeficiency Syndrome, or AIDS

HIV attacks the bodys own immune system, specifically killing off CD4+ cells, or T-cells. Left untreated, HIV reduces the number of T-cells in the body, leading to AIDs, a condition where the body cannot fight off common infections and disease.

Currently there are over 30 antiretroviral drugs, or ART, approved by the U.S. Food and Drug Administration (“FDA”) to treat HIV patients but these drugs are expensive, require daily adherence and can have significant side effects over time. In addition, approximately 1 million people, including in high-income countries, continue to die from HIV/AIDS due to resistance to ART or lack of access. Today there are no treatments that can eliminate the reservoir of cells that contain HIV from the body. In other words, treatment is life-long.

There have been several efforts to cure HIV by re-engineering a person’s own T-cells so that such cells no longer express C-C chemokine receptor type 5, also known as CCR5, which is an essential co-receptor for HIV to enter T-cells. A mutation that blocks expression of CCR5 on T-cells occurs in a small percentage of people with no known adverse effects. The “Berlin patient”, and more recently the “London patient” are HIV- positive persons who developed cancer and were treated with a bone marrow transplant with cells derived from persons with a naturally occurring deletion of CCR5. The Berlin and London patients seem to be effectively cured from HIV providing a proof of concept that HIV can be cured. However, because the transplanted cells come from another person, such transplants are highly toxic and can result in death in a significant proportion of patients. Given the success with these two patients, several researchers and companies have attempted to replicate the experience of such patients by genetically modifying the T-cells of the HIV-positive patients themselves and reinfusing them with T-cells that do not express CCR5. Because the transplanted cells are from the same person, the risks to the patient are much lower. The uptake, or engraftment of the modified, reinfused cells, however, has not been optimal, leading to a failure to achieve a cure. In addition, the transplant conditioning that has been used is myeloablative chemotherapy, wiping out the patient’s immune system, which has inherent risks and can have long-term side effects including the risk of developing cancer.

ENOB-HV-01 is a novel, proprietary approach with the potential to overcome the failures of recent efforts. The intervention: 1) provides gene-modified, reinfused cells with a competitive advantage over non-modified cells in the HIV-positive person, with the potential to significantly increase engraftment; and 2) avoids the need for myeloablative chemotherapy and, in fact, could potentially be given on an outpatient basis. The Company met with the FDAs INTERACT team on June 2, 2020. INTERACT is the first available FDA interaction and is a key step in the process towards a potential Investigational New Drug (IND) to study First-in-Human products potentially leading to marketing authorization via Biologics License Application (BLA). The FDAs Center for Biologics Evaluation and Research (CBER) has numerous INTERACT requests and only grants meetings that are deemed appropriate for this early FDA engagement. The Enochian management team considered the meeting to have been successful with strong alignment between Enochian’s approach to developing ENOB-HV-01 and the comments of the FDA reviewers.

Initial scientific findings from a mouse study on the ENOB-HV-01 approach were presented at the annual conference of the American Society of Cell and Gene Therapy (ASCGT) in May 2020.

We are also developing ENOB-HV-11 and ENOB-HV-12 that will utilize a novel cellular- and immunotherapy approach that could potentially provide for a preventative vaccine and a therapeutic vaccine, respectively. A non-human primate study is in process.

We are in the early discovery phase of two additional product candidates related to our HIV pipeline. ENOB-HV-31, which is an in vivo gene therapy, and ENOB-HV-32, which is a peptide drug for packaging and distribution.

Hepatitis B (HBV)

Despite the availability of an effective vaccine, Hepatitis B Virus (HBV) is the worlds most common serious liver infection. It is the leading cause of liver cancer and the second leading cause of cancer deaths in the world. Two billion people have been infected with HBV, approximately 250 million have chronic HBV infection, and nearly one million people die every year.

Current efforts to develop novel treatment or cure largely focus on approaches to deplete the pool of a certain type of HBV DNA. Enochian has partnered with Seraph Research Institute to develop an innovative approach to co-opt HBV polymerase to induce the death of liver cells infected with the virus.

The initial in vitro and in vivo work was presented at the biannual HEP DART meeting in December of 2019, where it was selected as one of the best new therapies/novel strategies. Additional data was presented at the annual conference of the ASCGT in May

2020.

On July 27, 2020, Enochian announced the creation of an HBV Scientific Advisory Board comprised of distinguished leaders in HBV disease, treatment and cure.

Cancer

Based on learning from peer-reviewed publications of Phase I/IIa trials, we have designed an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors. Initial preclinical in vitro studies have been encouraging. We plan to initially target pancreatic cancer, triple-negative breast cancer, glioblastoma, and renal cell carcinoma. The platform might also allow for non-specific immune enhancement that could have impact against a broad array of solid tumors. As with HIV, our approach would potentially allow for outpatient therapy without ablating or significantly impairing the patient’s immune system, as many current approaches require.

Recent Developments

On July 8, 2020, we entered into a purchase agreement (the “LPC Purchase Agreement”) with Lincoln Park Capital Fund, LLC, (“LPC”), pursuant to which LPC is committed to purchase, and we have the right, but not the obligation, to sell to LPC up to an aggregate of $20,000,000 of our Common Stock, subject to certain limitations and conditions set forth in the LPC Purchase Agreement, including a limitation on the number of shares of Common Stock we can put to LPC and the pricing parameters for the sales, and we agreed to issue 139,567 shares of our Common Stock as commitment shares. (see Note 7)

Corporate History

On February 16, 2018, we completed our acquisition of Enochian Biopharma pursuant to an acquisition agreement, dated January 12, 2018, by and among the Registrant, its wholly owned subsidiary DanDrit Acquisition Sub, Inc., Enochian Biopharma and Weird Science with Enochian Biopharma surviving as a wholly owned subsidiary of the Registrant. As consideration for the acquisition, the stockholders of Enochian Biopharma received (i) 18,081,962 shares of Common Stock and (ii) the right to receive Contingent Shares pro rata upon the exercise or conversion of warrants, which were outstanding at closing (See Note 7.)

COVID-19 Outlook

During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (COVID-19). The pandemic has significantly affected the economic conditions in the U.S. A number of states, counties and municipalities issued orders requiring persons who were not engaged in essential activities and businesses to remain at home. On March 27, 2020, the US enacted the Coronavirus Aid, Relief and Economic Security Aid (“CARES Act”) to help stimulate an economic recovery and additional legislation related to COVID-19 has been proposed; however, there are no reliable estimates of how long the pandemic will last or how many people are likely to be affected by it. No one knows what over-all effects the COVID-19 pandemic will have on economic conditions during the remainder of 2020.

Results of Operations for the three months ended September 30, 2020 compared to the three months ended September 30, 2019

The following table sets forth our revenues, expenses and net loss for the three months ended September 30, 2020 and September 30, 2019. The financial information below is derived from our unaudited condensed consolidated financial statements.

	For the Three Months
	Ended
	September 30, (Unaudited)
	2020			2019
Revenues	$	—		$	—

Cost of Goods Sold	$	—		$	—

Gross profit (Loss)	$	—		$	—

Operating Expenses
General and administrative expenses		1,777,923			1,900,812
Research and development expenses		1,050,376			520,192
Depreciation and amortization		30,458			21,481

Total Operating Expense	$	2,858,757		$	2,442,485

LOSS FROM OPERATIONS	$	(2,858,787	)	$	(2,442,485	)

Other Income (Expense)
Change in fair value of contingent consideration		427,400			(1,942,000	)
Interest income (expense)		92,313			—
Gain (loss) on currency transactions					286,755
Interest and other income		4,306			14,553
Total Other (Expense) Income		339,393			(1,640,692	)

Loss Before Income Taxes		(2,519,365	)		(4,083,177	)

Income Tax Benefit	$	122,794		$	—

NET LOSS	$	(2,396,570	)	$	(4,083,177	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.05	)	$	(0.09	)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED		46,605,118			46,241,315

Revenues

Revenues from operations for the three months ended September 30, 2020, and September 30, 2019 were $0 and $0, respectively.

Cost of Goods Sold

Our cost of goods sold was $0 and $0 during the three months ended September 30, 2020, and September 30, 2019, respectively.

Gross profit (Loss)

Gross profit for the three months ended September 30, 2020, and September 30, 2019 was $0 and $0, respectively.

Expenses

Our operating expenses for the three months ended September 30, 2020, and September 30, 2019 were $2,858,757 and $2,442,485, respectively, representing an increase of $416,272, or approximately 17%. The increase in operating expenses primarily relate to the HBV License Agreement.

General and administrative expenses for the three months ended September 30, 2020, and September 30, 2019 were $1,777,923 and $1,900,812, respectively, representing a decrease of $122,889, or approximately 6.5%. The decrease in general and administrative expenses is an aggregate of individual immaterial variances.

Research and development expenses for the three months ended September 30, 2020 and September 30, 2019 were $1,050,376 and $520,192, respectively, representing an increase of $530,184 or approximately 102%. The increases in research and development expenses are primarily due to the HBV License Agreement related payments of $833,500, offset by the reduction of $300,000 HIV License Agreement payments paid in 2019 that contractually expired in February 2020. All other R&D costs have remained relatively stable during this period.

The Company recorded other income of $339,393 for the three months ended September 30, 2020, compared to other (expense) of ($1,640,692) for the three months ended September 30, 2019, representing an increase of $1,980,085. The increase in other income (expense) is primarily attributable to the change in fair value of the contingent consideration liability related to the Enochian BioPharma Acquisition of $2,369,400, offset by the increase in interest expense of $92,313 related to our notes payables, and the decrease in gain on currency transactions that occurred in the prior year.

Net Loss

Net loss for the three months ended September 30, 2020, and September 30, 2019, was ($2,396,570) or ($0.05) per share and ($4,083,177) or ($0.09) per share, respectively, representing a decrease in loss of $1,686,607, or approximately 41%. The decrease in loss was primarily due to the increase in fair value of the contingent consideration of $2,369,400, offset by the increase in research and development expenses of $530,184 primarily related to the HBV License Agreement, and the decrease in gain on currency transactions of $286,755 from the prior year, and the tax benefit of $122,794 related to R&D tax credit received by our Danish subsidiary for prior years.

Liquidity and Capital Resources

We have historically satisfied our capital and liquidity requirements through funding from shareholders, the issuance of convertible notes and the sale of our Common Stock and warrants. We currently have no sales revenue to support our current operations and we expect this to be the case until our therapies or products are approved for marketing in the United States and Europe. Even if we are successful in having our therapies or products approved for sale in the United States and Europe, we cannot guarantee that a market for the product will develop. We may never be profitable. At this time, we believe we have sufficient liquidity and access to committed funds to fund our operations for the next twelve months.

At this time, we believe we have sufficient liquidity and access to committed funds to fund our operations for the next twelve months. We may need additional funds for (a) purchase of equipment and, (b) research and development, specifically to open an Investigational New Drug Application (IND) (The first step in the drug review process by the FDA) for ENOB-HV01, to continue our research and development of ENOB-HV11/12, to fund the HBV License Agreement in furtherance of the Treatment for Hepatitis B, and possible future strategic acquisitions of businesses, products or technologies complementary to our business. If additional funds are required, we may raise such funds from time to time through public or private sales of our equity or debt securities. Such financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely affect our growth plans and our financial condition and results of operations.

As of September 30, 2020, the Company had $5,965,661 in cash and working capital of $5,233,356 as compared to $8,696,361 in cash and working capital of $7,606,411 as of June 30, 2020, a decrease of 31.4 % and 31.2%, respectively.

Assets

Total assets at September 30, 2020, were $175,133,368 compared to $178,102,059 as of June 30, 2020. The decrease in total assets were primarily due to the decrease in cash of $2,730,700. The change is primarily attributed to the following expenditures, $1,050,376 in research and development costs primarily related to the HBV License Agreement, and general and administrative expenses of $1,010,738 net of non-cash items.

Liabilities

Total Liabilities at September 30, 2020, were $10,903,132 compared to $11,829,798 as of June 30, 2020. The decrease in total liabilities were primarily related to reduction in accounts payable trade that totaled approximately $310,501 due to timing, and the decrease of approximately $427,400 in the contingent consideration liability as a result of mark to market adjustment.

Following is a summary of the Company’s cash flows (used by) provided by operating, investing, and financing activities:

	Three Months Ended September 30, 2020			Three Months Ended September 30, 2019
Net Cash (Used by) Operating Activities	$	(2,755,665	)	$	(1,800,587	)
Net Cash (Used by) Investing Activities		—			(68,616	)
Net Cash Provided by Financing Activities		—			1,000,000
(Loss) Gain on Currency Translation		24,965			(274,769	)
(Decrease) in Cash and Cash Equivalents	$	(2,730,700	)	$	(1,143,972	)

Cash Flows

Cash used in operating activities for the three months ended September 30, 2020, and September 30, 2019 was ($2,755,665) and ($1,800,587), respectively. Cash used in operating activities during the current period included $1,050,376 in research and development costs primarily related to the HBV License Agreement, and general and administrative expenses of $1,301,782 net of non-cash items, and the payment of approximately $200,000 related to prior year accruals

There were no investing activities during the three months ended September 30, 2020, and $68,616 for the three months ended September 30, 2019.

Cash provided by financing activities for the three months ended September 30, 2020 and September 30, 2019, was $0 and $1,000,000, respectively. There were no financing activities during the three months ended September 30, 2020. For the three months ended September 30, 2019, the Company received financing from the exercising of warrants held by shareholders.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Significant Accounting Policies and Critical Accounting Estimates

The methods, estimates, and judgments that we use in applying our accounting policies have a significant impact on the results that we report in our financial statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result, of the need to make estimates regarding matters that are inherently uncertain.

For a full explanation of our accounting policies, see Note 1 to the unaudited condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a “smaller reporting company” as defined by Rule 12b-2 of the Securities Exchange Act of 1934, the Company is not required to provide the information required by this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our Principal Executive Officer and Chief Financial Officer (the “Certifying Officers”) are responsible for establishing and maintaining disclosure controls and procedures for the Company. The Certifying Officers have designed such disclosure controls and procedures to ensure that material information is made known to them, particularly during the period in which this Report was prepared.

The Certifying Officers are responsible for establishing and maintaining adequate internal control over financial reporting for the Company used the “Internal Control over Financial Reporting Integrated Framework” issued by Committee of Sponsoring Organizations (“COSO”) to conduct an extensive review of the Company’s “disclosure controls and procedures” (as defined in the Exchange Act, Rules 13a-15(e) and 15-d-15(e)) as of the end of each of the periods covered by this Report (the “Evaluation Date”). Based upon that evaluation, the Certifying Officers concluded that, as of September 30, 2020, our disclosure controls and procedures were not effective in ensuring that the information we were required to disclose in reports that we file or submit under the Securities and Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. The deficiencies are attributed to the fact that the Company does not have adequate resources to address complex accounting issues, as well as an inadequate number of persons to whom it can segregate accounting tasks within the Company so as to ensure the segregation of duties between those persons who approve and issue payment from those persons who are responsible to record and reconcile such transactions within the Company’s accounting system. These control deficiencies will be monitored and attention will be given to the matter as we continue to accelerate through our current growth stage.

The Certifying Officers based their conclusion on the fact that the Company has identified material weaknesses in controls over financial reporting, detailed below. In order to reduce the impact of these weaknesses to an acceptable level, the Company has contracted with consultants with expertise in U.S. GAAP and SEC financial reporting standards to review and compile all financial information prior to filing that information with the SEC. However, even with the added expertise of these consultants, we still expect to be deficient in our internal controls over disclosure and procedures until sufficient capital is available to hire the appropriate internal accounting staff and individuals with requisite GAAP and SEC financial reporting knowledge. There have been no significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting during the three ended September 30, 2020 that have materially affected or are reasonably likely to materially affect our internal controls.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

There are presently no material pending legal proceedings to which the Company or any of its subsidiaries, is a party or as to which any of its property is subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

Item 1A. Risk Factors.

Risk factors that may affect our business and financial results are discussed within Item 1A “Risk Factors” of our annual report for the fiscal year ended June 30, 2020 on Form 10-K (“2020 Form 10-K”) filed with the SEC on September 23, 2020. There have been no material changes to the disclosures relating to this item from those set forth in our 2020 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Item 6. Exhibits.

(a)

Exhibits required by Item 601 of Regulation S-K.

Exhibit No.		Description

10.1*		Purchase Agreement, dated July 8, 2020, by and between the Company and Lincoln Park Capital Fund, LLC (1)

10.2*		Registration Rights Agreement, dated July 8, 2020, by and between the Company and Lincoln Park Capital Fund, LLC (1)

31.1**		Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934

31.2**		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934

32.1***		Certification of Principal Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350

32.2***		Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350

101.INS		XBRL Instance Document*

101.SCH		XBRL Taxonomy Extension Schema*

101.CAL		XBRL Taxonomy Extension Calculation Linkbase*

101.DEF		XBRL Taxonomy Extension Definition Linkbase*

101.LAB		XBRL Taxonomy Extension Label Linkbase*

101.PRE		XBRL Taxonomy Extension Presentation Linkbase*

Filed as an exhibit to the Company’s Current Report on Form 8-K, filed with the SEC on July 14, 2020.

Filed herewith.

***

Furnished herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 12, 2020	ENOCHIAN BIOSCIENCES, INC.

	By:	/s/ Mark Dybul
		Mark Dybul
		Executive Vice Chair
		(Principal Executive Officer)


	By:	/s/ Luisa Puche
		Luisa Puche
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 e2200_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

OFFICER’S CERTIFICATE

PURSUANT TO SECTION 302

I, Mark Dybul, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2020 of Enochian Biosciences, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 12, 2020	By:	/s/ Mark Dybul
	Name:	Mark Dybul
	Title:	Executive Vice Chair (Principal Executive Officer)

EX-31.2 3 e2200_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

OFFICER’S CERTIFICATE

PURSUANT TO SECTION 302

I, Luisa Puche, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2020 of Enochian Biosciences, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 12, 2020

By:

/s/ Luisa Puche

Name:

Luisa Puche

Title:

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 e2200_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Enochian Biosciences, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: November 12, 2020	By:	/s/ Mark Dybul
	Name:	Mark Dybul
	Title:	Executive Vice Chair (Principal Executive Officer)

A signed original of this written statement required by Section 906, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.

EX-32.2 5 e2200_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Enochian Biosciences, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: November 12, 2020	By:	/s/ Luisa Puche
	Name:	Luisa Puche
	Title:	Chief Financial Officer (Principal Financial Officer)

EX-101.INS 6 enob-20200930.xml XBRL INSTANCE FILE 0001527728 2020-09-30 0001527728 2020-06-30 0001527728 2020-07-01 2020-09-30 0001527728 2019-07-01 2019-09-30 0001527728 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001527728 enob:AgreementAndPlanOfMergerAgreementAxisMember enob:EBIAndWeirdScienceLLCMember 2018-02-15 2018-02-16 0001527728 enob:LabEquipmentAndInstrumentsMember srt:MinimumMember 2020-07-01 2020-09-30 0001527728 enob:LabEquipmentAndInstrumentsMember srt:MaximumMember 2020-07-01 2020-09-30 0001527728 us-gaap:LeaseholdImprovementsMember 2020-07-01 2020-09-30 0001527728 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2020-07-01 2020-09-30 0001527728 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2020-07-01 2020-09-30 0001527728 enob:LabEquipmentAndInstrumentsMember 2020-09-30 0001527728 us-gaap:LeaseholdImprovementsMember 2020-09-30 0001527728 us-gaap:FurnitureAndFixturesMember 2020-09-30 0001527728 enob:LabEquipmentAndInstrumentsMember 2020-06-30 0001527728 us-gaap:LeaseholdImprovementsMember 2020-06-30 0001527728 us-gaap:FurnitureAndFixturesMember 2020-06-30 0001527728 enob:AccumulatedAmortizationMember 2020-06-30 0001527728 enob:AccumulatedAmortizationMember 2020-07-01 2020-09-30 0001527728 enob:AccumulatedAmortizationMember 2020-09-30 0001527728 us-gaap:PatentsMember 2020-06-30 0001527728 us-gaap:PatentsMember 2020-07-01 2020-09-30 0001527728 us-gaap:PatentsMember 2020-09-30 0001527728 us-gaap:LicensingAgreementsMember 2020-09-30 0001527728 us-gaap:LicensingAgreementsMember 2020-06-30 0001527728 us-gaap:GoodwillMember 2020-09-30 0001527728 us-gaap:GoodwillMember 2020-06-30 0001527728 2017-11-01 2017-11-13 0001527728 2018-06-01 2018-06-19 0001527728 enob:EnochianBiosciencesMember srt:MinimumMember 2020-07-01 2020-09-30 0001527728 enob:EnochianBiosciencesMember srt:MaximumMember 2020-07-01 2020-09-30 0001527728 enob:EnochianBiosciencesMember 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember 2020-09-30 0001527728 enob:CommonStockPurchaseWarrantsMember 2020-07-01 2020-09-30 0001527728 enob:CommonStockPurchaseWarrantsMember 2020-06-30 0001527728 enob:CommonStockPurchaseWarrantsMember 2020-09-30 0001527728 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001527728 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0001527728 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001527728 us-gaap:RestrictedStockUnitsRSUMember enob:ExercisePriceRange14Member 2020-07-01 2020-09-30 0001527728 us-gaap:RestrictedStockUnitsRSUMember enob:ExercisePriceRange14Member 2020-09-30 0001527728 enob:EquityIncentivePlan2019Member 2014-02-05 2014-02-06 0001527728 enob:EquityIncentivePlan2019Member 2020-07-01 2020-09-30 0001527728 enob:EquityIncentivePlan2014Member 2014-02-06 0001527728 enob:DanDritDenmarkMember 2020-09-30 0001527728 enob:ConsultingAgreementMember enob:GTechMember 2019-07-01 2019-09-30 0001527728 enob:ConsultingAgreementMember enob:GTechMember 2020-07-01 2020-09-30 0001527728 enob:ConsultingAgreementMember enob:GTechMember 2018-07-01 2018-07-09 0001527728 enob:LicenseAgreementMember enob:GTechMember 2020-01-01 2020-01-31 0001527728 enob:LicenseAgreementMember enob:GTechMember 2020-02-01 2020-02-06 0001527728 enob:NotePayableMember 2020-07-01 2020-09-30 0001527728 enob:NotePayableMember 2020-09-30 0001527728 enob:ConvertibleNotesPayablesMember 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember 2020-06-30 0001527728 2019-06-30 0001527728 2019-09-30 0001527728 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001527728 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001527728 us-gaap:CommonStockMember 2020-06-30 0001527728 us-gaap:CommonStockMember 2020-09-30 0001527728 us-gaap:CommonStockMember 2019-06-30 0001527728 us-gaap:CommonStockMember 2019-09-30 0001527728 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001527728 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001527728 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001527728 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001527728 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001527728 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001527728 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001527728 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001527728 us-gaap:RetainedEarningsMember 2020-06-30 0001527728 us-gaap:RetainedEarningsMember 2020-09-30 0001527728 us-gaap:RetainedEarningsMember 2019-06-30 0001527728 us-gaap:RetainedEarningsMember 2019-09-30 0001527728 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001527728 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001527728 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001527728 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001527728 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001527728 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001527728 enob:AgreementAndPlanOfMergerAgreementAxisMember enob:EBIAndWeirdScienceLLCMember 2020-07-01 2020-09-30 0001527728 enob:AgreementAndPlanOfMergerAgreementAxisMember enob:EBIAndWeirdScienceLLCMember 2018-02-16 0001527728 enob:AcquisitionOfEnochianBiopharmaMember 2020-07-01 2020-09-30 0001527728 enob:AcquisitionOfEnochianBiopharmaMember 2020-09-30 0001527728 us-gaap:PatentsMember 2019-07-01 2019-09-30 0001527728 enob:ConvertibleNotesPayablesMember 2020-02-06 0001527728 enob:ConvertibleNotesPayablesMember 2019-07-01 2020-02-06 0001527728 enob:ConvertibleNotesPayablesMember 2020-06-30 0001527728 enob:NotePayableMember 2020-03-30 0001527728 enob:NotePayableMember 2019-07-01 2020-03-30 0001527728 enob:CommonStockPurchaseWarrantsMember 2019-07-01 2020-06-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange1Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange2Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange3Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange4Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange5Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange6Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange7Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange8Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange9Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange10Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange11Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange12Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange13Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange14Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange15Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange16Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange1Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange2Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange3Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange4Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange5Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange6Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange7Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange8Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange9Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange10Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange11Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange12Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange13Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange14Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange15Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange16Member 2020-09-30 0001527728 us-gaap:WarrantMember enob:ExercisePriceRange20Member 2020-07-01 2020-09-30 0001527728 us-gaap:WarrantMember enob:ExercisePriceRange21Member 2020-07-01 2020-09-30 0001527728 us-gaap:WarrantMember 2020-07-01 2020-09-30 0001527728 us-gaap:WarrantMember enob:ExercisePriceRange20Member 2020-09-30 0001527728 us-gaap:WarrantMember enob:ExercisePriceRange21Member 2020-09-30 0001527728 us-gaap:WarrantMember 2020-09-30 0001527728 enob:LincolnParkMember enob:PurchaseAgreementMember 2020-07-01 2020-07-08 0001527728 us-gaap:StockOptionMember 2019-07-01 2019-07-03 0001527728 enob:EnochianBiosciencesMember 2019-07-01 2019-07-03 0001527728 enob:EnochianBiosciencesMember 2019-07-03 0001527728 enob:BoardOfDirectorsMember 2019-07-01 2019-09-30 0001527728 enob:SeniorEmployeesMember 2019-07-01 2019-09-30 0001527728 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange17Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange18Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange19Member 2020-07-01 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange17Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange18Member 2020-09-30 0001527728 us-gaap:EmployeeStockOptionMember enob:ExercisePriceRange19Member 2020-09-30 0001527728 2020-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Enochian Biosciences Inc 0001527728 false --06-30 Q1 2021 10-Q 2020-09-30 Yes 46636976 Non-accelerated Filer false true false 001-38758 DE Yes

46636976

46497409

107804

175133368

178102059

1637878

1703859

154824000

76834

77323

-66584768

-64188198

2858757

2442485

1050376

520192

375000

50000

-2396570

-4083177

-2396570

-4083177

-0.05

-0.09

-2368181

-4361833

-28389

278656

30458

21481

2755034

3182434

-427400

5965661

8696361

18081962

1438122

4115883

3441375

P20Y

316950

226266

9206

7744

31850 130000

P4Y

P7Y

P10Y

P4Y

P7Y

931131

534527

224629

171975

534527

224629

171975

179558

153013

26545

21481

76834

77323

299175

312422

-221852

-235588

-3913 -3913 0

3424

-9823

13247

166464000

154824000

11640000

On November 13, 2017, Enochian entered into a Lease Agreement for a term of five years and two months from November 1, 2017 (the "Term") with Plaza Medical Office Building, LLC, a California limited liability company (the "Landlord"), as landlord, pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increases by 3% each year, and ranges from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The Company received $70,800 in tenant improvement allowance in the form of free rent applied over 10 months in equal installments beginning in January of 2018.

P6Y2M27D

0.0399

P5Y6M

0.7992

0.8003

0.993

0.0026

0.0034

0.0013

0.0000

1129638

1105442

55762

23006

11719

5195

5063

7282

10000

50749

4124

9183

6000

15679

7759

60000

24001

300000

1413122

25000

1438122

4317

10563

519235

P8Y11M15D

P1Y8M26D

P9M7D

P1Y8M26D

P9Y5M9D

P9Y5M1D

P9Y10M3D

P7Y10M3D

P9Y9M18D

P8Y10M25D

P9Y2M30D

P8Y10M25D

P8Y10M10D

P8Y10M25D

P7Y11M19D

P8Y0M11D

P8Y8M9D

P8Y5M9D

P8Y1M24D

P8Y6M10D

P8Y5M1D

P9Y5M1D

6.72

6.78

2.69

3.26

3.84

3.85

3.95

4.12

4.63

4.8

4.9

5.74

5.8

6.15

6.25

6.5

1.30

8.00

1.42

6.95

7.1

472385

1438122

5063

10000

4124

9183

6000

15679

7759

20000

24001

300000

1413122

25000

1438122

4317

10563

55695

P8Y2M1D

P1Y8M26D

P9M7D

P7Y10M3D

P8Y10M25D

P8Y10M10D

P7Y11M19D

P8Y0M11D

P8Y8M9D

P8Y5M9D

P8Y1M24D

P8Y6M10D

P8Y5M1D

P7Y7M6D

6.50

1.42

3.95

4.63

4.9

5.74

5.8

6.15

6.25

6.5

1.30

8.00

1.42

6.95

7.1

24196

1129638

13470

20000

500000

3.93

P9Y2M8D P10Y

56990

107931

10000

6.15 6.15

6.15

77249

82237

1206000

24196 472385

836754

1438122 Board approved and on October 31, 2019, the Company’s shareholders adopted the Enochian’s 2019 Equity Incentive Plan (the “2019 Plan”), which replaced the 2014 Plan. The 2019 Plan authorized options to be awarded to not exceed the sum of (1) 6,000,000 new shares of Common Stock, and (2) the number of shares of Common Stock available for the grant of awards as of the effective date under the 2014 Plan that, after the effective date of the 2019 Plan, expires, or is terminated, surrendered, or forfeited for any reason without issuance of shares. The remaining shares of Common Stock available for grant related to the 2014 Plan was of 655,769 as of the effective date, this amount along with the new 6,000,000 shares totals 6,655,769 shares of Common Stock available to grant immediately after the effective date of the 2019 Plan.

4988

0.02

1200000

600000

5000000

25000

144500

400000 433500

0.06

2023-02-06

2021-11-30

2020-02-06

2020-03-30

1737611

574821

253384

246004

298305

348495

255137

-2858757

-2442485

30458

21481

1777923

1900812

46605118

46241315

-122794

-2519365

-4083177

339393

-1640692

4306

14553

286755

-92313

427400 -1942000

5965661

8696361

12282224

11138252

168316262

168382732

137550

11640000

751573

778118

6065533

8941209

99872

242866

1982

10903132

11829798

4654765

4580787

1200000

1461156

1531779

2755034

3182434

21516000

832177

1334798

276456

271285

273345

470636

6000

282376

592877

175133368

178102059

164230236

166272261

173099937

172182114

4650

4664

4527

4627

230497225

230823367

225765432

229209342

-64188198

-66584768

-52771840

-56855017

-41416

-13027

101818

-176838

-13027

-41416

230823367

230497225

4664

4650

-2755665

-1800587

-65452

-60256

-197291

-136424

-310501

71022

-142994

-135793

-1982

-6098

73978

-65981

-68866

326156

234010

427400 -1942000

-68616

68616

-2730700

-1143972

24965

-274769

1000000

42365

2210000

46497409

46636976

45273924

46273924

500000 1000000 50 999950

500000

2210000

2209950

2200000

326156

234010

326156

234010

28389

-278656

28389

-278656

139567

-14

NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES     Business– Enochian BioSciences Inc., (“Enochian”, or “Registrant”, and together with its subsidiaries, the “Company”, “we” or “us”) is a pre-clinical stage biotechnology company committed to using our genetically modified cellular and immune-therapy technologies to prevent or potentially cure HIV, Hepatitis B (HBV), and to provide potentially life-long cancer remission of some of the deadliest cancers.    Basis of Presentation- The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and follows the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2020 and 2019 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s June 30, 2020 audited financial statements. The results of operations for the periods ended September 30, 2020 and 2019 are not necessarily indicative of the operating results for the full year.   Consolidation - For the three months ended September 30, 2020 and 2019, the consolidated financial statements include the accounts and operations of the Registrant, and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.   Reclassification–Certain amounts in the prior period financial statements have been reclassified to conform to the current presentation. For the three months ended September 30, 2019, we reclassified consulting expense of $31,850, to general and administrative expenses.   Accounting Estimates - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, and fair value of equity instruments issued.   COVID-19- During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (COVID-19). The pandemic has significantly affected the economic conditions in the U.S. A number of states, counties and municipalities issued orders requiring persons who were not engaged in essential activities and businesses to remain at home. On March 27, 2020, the US enacted the Coronavirus Aid, Relief and Economic Security Aid (“CARES Act”) to help stimulate an economic recovery; however, there are no reliable estimates of how long the pandemic will last or how many people are likely to be affected by it. No one knows what over-all effects the COVID-19 pandemic will have on economic conditions during the remainder of the fiscal year.   Our senior management team is monitoring COVID-19’s impact daily and will continue to adjust our operations as necessary. However, the impact of this event on the Company’s results of operations, financial position, and liquidity or capital resources cannot be reasonably estimated at this time.   Functional Currency & Foreign currency translation - The functional currency of Enochian Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ended September 30, 2020, and June 30, 2020, and September 30, 2019. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.   Cash and Cash Equivalents —The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held in financial institutions in Denmark and in the United States in excess of federally insured States amounts at September 30, 2020 and June 30, 2020 of $5,965,661 and $8,696,361, respectively.   Property and Equipment — Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets, which range from four to ten years (See Note 3).   Intangible Assets - The Company has both Definite and Indefinite life intangible assets.   Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.   Indefinite life intangible assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. License agreement costs represent the Fair Value of the license agreement on the date acquired and are tested annually for impairment. The fair value analysis performed on the license agreements, and the fair value analysis performed on goodwill supported that both indefinite life intangible assets are not impaired as of June 30, 2020, and no impairment is deemed necessary as of September 30, 2020. (See Note 4)   Goodwill —Goodwill is not amortized but is evaluated for impairment annually as of June 30th or whenever events or changes in circumstances indicate the carrying value may not be recoverable.   We test for goodwill impairment at the reporting unit level, which is one level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of the reporting unit and is based on discounted cash flows or relative market-based approaches. If the fair value exceeds carrying value, then it is concluded that no goodwill impairment has occurred. If the carrying value of the reporting unit exceeds its fair value, a second step is required to measure possible goodwill impairment loss. The second step includes hypothetically valuing the tangible and intangible assets and liabilities of the reporting unit as if the reporting unit had been acquired in a business combination. Then, the implied fair value of the reporting unit’s goodwill is compared to the carrying value of that goodwill. If the carrying value of the reporting unit’s goodwill exceeds the implied fair value of the goodwill, we recognize an impairment loss in an amount equal to the excess, not to exceed the carrying value.   The carrying value of goodwill at September 30, 2020, was $11,640,000. We do not believe there is a reasonable likelihood that there will be a material change in the future estimates or assumptions we use to test for impairment losses on goodwill. However, if actual results are not consistent with our estimates or assumptions, we may be exposed to an impairment charge that could be material.   Impairment of Long-Lived Assets — Long-lived assets, such as property, plant, and equipment, patents and licenses are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.   Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.   Leases — In accordance with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information available at the commencement date in determining the present value of the future payments.   Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statement of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited condensed consolidated statements of operations.   The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred. (See Note 5).   Research and Development Expenses — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of the HIV, HBV, and Cancer therapies and technologies for use in the prevention, treatment, amelioration of and/or therapy for HIV, HBV, and Cancer. Research and development expenses for the three months ended September 30, 2020 and 2019, amounted to $1,050,376, and $520,192, respectively.   Income Taxes — The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach for accounting for income taxes. During the quarter ended September 30, 2020, the Company’s Danish subsidiary received a payment for an R&D tax credit owed under Danish statutory tax laws in the amount of $122,831.   Loss Per Share — The Company calculates earnings/(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of shares of Common Stock, par value 0.0001 per share (“Common Stock”) outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive shares of Common Stock. Potential shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised. Because of the net loss for the three ended September 30, 2020 and 2019, the dilutive shares for both periods were excluded from the Diluted EPS calculation as the effect of these potential shares of Common Stock is anti-dilutive. The Company had 4,115,883 and 3,441,375 potential shares of Common Stock excluded from the Diluted EPS calculation as of September 30, 2020 and September 30, 2019.   Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; width: 30px; text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 15px; text-align: justify">●</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 30px; text-align: justify"> </td> <td style="vertical-align: top; width: 15px">●</td> <td style="text-align: justify">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 30px; text-align: justify"> </td> <td style="vertical-align: top; width: 15px">●</td> <td style="text-align: justify">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </td></tr> </table>   The Company adopted ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements, which amends certain disclosures requirements over fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on July 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (See Note 2-Fair Value of Financial Instruments for more information about the Company’s fair value classifications.)   Stock Options and Restricted Share Units - The Company has granted stock options, restricted share units (“RSU’s) and warrants. The Company accounts for options in accordance with the provisions of FASB ASC Topic 718, Compensation - Stock Compensation. Stock based compensation costs for the vesting of options and RSU’s granted to officers, board members, employees and consultants for the three months ended September 30, 2020 and 2019 were $326,156 and $234,010, respectively.   Stock-Based Compensation -The Company records stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued and are recognized over the employees required service period, which is generally the vesting period. No shares were issued for services for the three months ended September 30, 2020 and 2019.   Recent Adopted Accounting Pronouncements    The Company adopted ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements, as of July 1, 2020 (Note 2).   Other recent accounting pronouncements issued by the FASB do not or are not believed by management to have a material impact on the Company’s present or future financial statements.

NOTE 2 — FAIR VALUE MEASUREMENT — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; width: 30px; text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 15px; text-align: justify">●</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 30px; text-align: justify"> </td> <td style="vertical-align: top; width: 15px">●</td> <td style="text-align: justify">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 30px; text-align: justify"> </td> <td style="vertical-align: top; width: 15px">●</td> <td style="text-align: justify">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </td></tr> </table>   The were no Level 1, 2 or 3 assets, nor and Level 1 or 2 liabilities as of September 30, 2020.   Level 3 liabilities held as of September 30, 2020 consisted of a contingent consideration liability related to the February 16, 2018 acquisition of Enochian BioPharma (the “Acquisition”). As consideration for the Acquisition, the stockholders of Enochian Biopharma received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive Contingent Shares pro rata upon the exercise of warrants, which were outstanding at closing. The contingent consideration liability was recorded at fair value of $21,516,000 at the time of acquisition and is subsequently remeasured to fair value at each reporting period. At September 30, 2020, 1,438,122 Contingent Shares are issuable in connection with the Acquisition of Enochian Biopharma.   The fair value of the contingent consideration liability is estimated using an option-pricing model. The key inputs to the model are all contractual or observable with the exception being volatility, which is computed, based on the Company’s underlying stock. The key inputs to valuing the contingent consideration liability on the date of acquisition and as of September 30, 2020, include the Company’s stock price on the valuation date of $3.58; the exercise price of the warrants of $1.30, the risk-free rate of .13% the expected volatility of the Company’s Common Stock of 99.3%, the digital call rate 54%, and the 1,438,122 of contingent shares remaining at the end of the period. Fair Value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value.   Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.   The following table sets forth the Level 3 liability at September 30, 2020, which is recorded on the balance sheet at fair value on a recurring basis. As required, these are classified based on the lowest level of input that is significant to the fair value measurement:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Fair Value Measurements at Reporting Date Using</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Quoted Prices in   Active Markets for Identical Assets Inputs</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Significant Other Observable Inputs</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Other Unobservable</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">(Level 1)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">(Level 2)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">(Level 3)</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Contingent Consideration Liability</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; width: 1%; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; width: 8%; padding-left: 10pt; text-align: right">  —</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; width: 1%; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; width: 8%; padding-left: 10pt; text-align: right">  —</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; width: 1%">$</td> <td style="border-bottom: black 1pt solid; width: 8%; text-align: right">2,755,034</td> <td style="width: 1%; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-align: justify; text-indent: -10pt">The roll forward of the contingent consideration liability is as follows:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-indent: -10pt">Balance June 30, 2020</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3,182,434</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt">Contingent Shares issued pursuant to the Acquisition Agreement</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Fair value adjustment</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">—</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">—</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(427,400</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Balance September 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,755,034</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 3 — PROPERTY AND EQUIPMENT   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Useful Life</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> June 30, 2020</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 69%">Lab Equipment and Instruments</td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: center">4-7</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">534,527</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">534,527</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Leasehold Improvements</td> <td> </td> <td style="text-align: center">10</td> <td> </td> <td>$</td> <td style="text-align: right">224,629</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">224,629</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Furniture Fixtures and Equipment</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center">4-7</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">$</td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">171,975</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">171,975</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td>$</td> <td style="text-align: right">931,131</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">931,131</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Less Accumulated Depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">$</td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">(179,558</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(153,013</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Net Property and Equipment</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">751,573</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">778,118</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   During the three months ended September 30, 2020, and 2019, respectively, the Company had depreciation expense of $26,545, and $21,481, respectively.

NOTE 5 — LEASES   Operating Leases — On November 13, 2017, Enochian entered into a Lease Agreement for a term of five years and two months from November 1, 2017 (the “Term”) with Plaza Medical Office Building, LLC, a California limited liability company (the “Landlord”), as landlord, pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increases by 3% each year, and ranges from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The Company received $70,800 in tenant improvement allowance in the form of free rent applied over 10 months in equal installments beginning in January of 2018.     On June 19, 2018, the Registrant entered into a Lease Agreement for a term of ten years from September 1, 2018 with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Registrant entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the remainder of the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050. The Company was entitled to $148,168 in contributions toward tenant improvements.   The Company identified and assessed the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities:   Expected lease term — The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably certain that the Company would exercise such options. The Company’s leases have remaining lease terms between 27 months and 83 months. As of September 30, 2020, the weighted-average remaining term is 6.24 years.   Incremental borrowing rate — The Company’s lease agreements do not provide an implicit rate. As the Company does not have any external borrowings for comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury Yield Curve rate that corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if borrowing on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. As of September 30, 2020, the weighted-average discount rate is 3.99%.   Lease and non-lease components — In certain cases the Company is required to pay for certain additional charges for operating costs, including insurance, maintenance, taxes, and other costs incurred, which are billed based on both usage and as a percentage of the Company’s share of total square footage. The Company determined that these costs are non-lease components and they are not included in the calculation of the lease liabilities because they are variable. Payments for these variable, non-lease components are considered variable lease costs and are recognized in the period in which the costs are incurred.   For the three months ended September 30, 2020, and September 30, 2019, lease expense charged to general and administrative expenses amounted to $89,684 and $101,521, respectively.   Below are the lease commitments for the next 5 years and thereafter:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Year Ending June 30th</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Lease Expense</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%; padding-left: 0.25in; text-indent: -9pt">2021</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">255,137</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.25in; text-indent: -9pt">2022</td> <td> </td> <td>$</td> <td style="text-align: right">348,495</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 0.25in; text-indent: -9pt">2023</td> <td> </td> <td>$</td> <td style="text-align: right">298,305</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.25in; text-indent: -9pt">2024</td> <td> </td> <td>$</td> <td style="text-align: right">246,004</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 0.25in; text-indent: -9pt">2025</td> <td> </td> <td>$</td> <td style="text-align: right">253,384</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.25in; text-indent: -9pt">Thereafter</td> <td> </td> <td>$</td> <td style="text-align: right">574,821</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt">Less imputed interest</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(238,535</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 0.5in; text-indent: -9pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,737,611</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 9 — RELATED PARTY TRANSACTIONS     On July 9, 2018, the Company entered into a consulting agreement with G-Tech to assist the Company with the development of the gene therapy and autologous and allogenic cell therapy modalities for the prevention, treatment, amelioration of HIV in humans, and with the development of a genetically enhanced Allogenic Dendritic Cell for use as a wide spectrum platform for various diseases (including but not limited to cancers and infectious diseases). (See Note 8)   On January 31, 2020, the Company entered into the HBV License Agreement by and among the Company, G Tech and SRI, whereby the Company acquired the HBV License for the Treatment. (See Note 8)

NOTE 10 — SUBSEQUENT EVENTS   In accordance with ASC 855-10, Company management reviewed all material events through the date of this report. There have been no subsequent events of a significant and reportable nature as of November 12, 2020.

Cash and Cash Equivalents —The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held in financial institutions in Denmark and in the United States in excess of federally insured States amounts at September 30, 2020 and June 30, 2020 of $5,965,661 and $8,696,361, respectively.

Property and Equipment — Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets, which range from four to ten years (See Note 3).

Intangible Assets - The Company has both Definite and Indefinite life intangible assets.   Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.   Indefinite life intangible assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. License agreement costs represent the Fair Value of the license agreement on the date acquired and are tested annually for impairment. The fair value analysis performed on the license agreements, and the fair value analysis performed on goodwill supported that both indefinite life intangible assets are not impaired as of June 30, 2020, and no impairment is deemed necessary as of September 30, 2020. (See Note 4)

Business– Enochian BioSciences Inc., (“Enochian”, or “Registrant”, and together with its subsidiaries, the “Company”, “we” or “us”) is a pre-clinical stage biotechnology company committed to using our genetically modified cellular and immune-therapy technologies to prevent or potentially cure HIV, Hepatitis B (HBV), and to provide potentially life-long cancer remission of some of the deadliest cancers.

Basis of Presentation- The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and follows the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2020 and 2019 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s June 30, 2020 audited financial statements. The results of operations for the periods ended September 30, 2020 and 2019 are not necessarily indicative of the operating results for the full year.

Consolidation - For the three months ended September 30, 2020 and 2019, the consolidated financial statements include the accounts and operations of the Registrant, and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.

Reclassification–Certain amounts in the prior period financial statements have been reclassified to conform to the current presentation. For the three months ended September 30, 2019, we reclassified consulting expense of $31,850, to general and administrative expenses.

Accounting Estimates - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, and fair value of equity instruments issued.

COVID-19- During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (COVID-19). The pandemic has significantly affected the economic conditions in the U.S. A number of states, counties and municipalities issued orders requiring persons who were not engaged in essential activities and businesses to remain at home. On March 27, 2020, the US enacted the Coronavirus Aid, Relief and Economic Security Aid (“CARES Act”) to help stimulate an economic recovery; however, there are no reliable estimates of how long the pandemic will last or how many people are likely to be affected by it. No one knows what over-all effects the COVID-19 pandemic will have on economic conditions during the remainder of the fiscal year.   Our senior management team is monitoring COVID-19’s impact daily and will continue to adjust our operations as necessary. However, the impact of this event on the Company’s results of operations, financial position, and liquidity or capital resources cannot be reasonably estimated at this time.

Functional Currency & Foreign currency translation - The functional currency of Enochian Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ended September 30, 2020, and June 30, 2020, and September 30, 2019. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.

Impairment of Long-Lived Assets — Long-lived assets, such as property, plant, and equipment, patents and licenses are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.   Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.

Leases — In accordance with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information available at the commencement date in determining the present value of the future payments.   Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statement of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited condensed consolidated statements of operations.   The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred. (See Note 5).

Research and Development Expenses — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of the HIV, HBV, and Cancer therapies and technologies for use in the prevention, treatment, amelioration of and/or therapy for HIV, HBV, and Cancer. Research and development expenses for the three months ended September 30, 2020 and 2019, amounted to $1,050,376, and $520,192, respectively.

Income Taxes — The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach for accounting for income taxes. During the quarter ended September 30, 2020, the Company’s Danish subsidiary received a payment for an R&D tax credit owed under Danish statutory tax laws in the amount of $122,831.

Loss Per Share — The Company calculates earnings/(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of shares of Common Stock, par value 0.0001 per share (“Common Stock”) outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive shares of Common Stock. Potential shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised. Because of the net loss for the three ended September 30, 2020 and 2019, the dilutive shares for both periods were excluded from the Diluted EPS calculation as the effect of these potential shares of Common Stock is anti-dilutive. The Company had 4,115,883 and 3,441,375 potential shares of Common Stock excluded from the Diluted EPS calculation as of September 30, 2020 and September 30, 2019.

Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; width: 30px; text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 15px; text-align: justify">●</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 30px; text-align: justify"> </td> <td style="vertical-align: top; width: 15px">●</td> <td style="text-align: justify">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 30px; text-align: justify"> </td> <td style="vertical-align: top; width: 15px">●</td> <td style="text-align: justify">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </td></tr> </table>   The Company adopted ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements, which amends certain disclosures requirements over fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on July 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (See Note 2-Fair Value of Financial Instruments for more information about the Company’s fair value classifications.)

Stock Options and Restricted Share Units - The Company has granted stock options, restricted share units (“RSU’s) and warrants. The Company accounts for options in accordance with the provisions of FASB ASC Topic 718, Compensation - Stock Compensation. Stock based compensation costs for the vesting of options and RSU’s granted to officers, board members, employees and consultants for the three months ended September 30, 2020 and 2019 were $326,156 and $234,010, respectively.

Stock-Based Compensation -The Company records stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued and are recognized over the employees required service period, which is generally the vesting period. No shares were issued for services for the three months ended September 30, 2020 and 2019.

Recent Adopted Accounting Pronouncements    The Company adopted ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements, as of July 1, 2020 (Note 2).   Other recent accounting pronouncements issued by the FASB do not or are not believed by management to have a material impact on the Company’s present or future financial statements.

The following table sets forth the Level 3 liability at September 30, 2020, which is recorded on the balance sheet at fair value on a recurring basis. As required, these are classified based on the lowest level of input that is significant to the fair value measurement:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Fair Value Measurements at Reporting Date Using</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Quoted Prices in   Active Markets for Identical Assets Inputs</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Significant Other Observable Inputs</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Other Unobservable</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">(Level 1)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">(Level 2)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">(Level 3)</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Contingent Consideration Liability</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; width: 1%; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; width: 8%; padding-left: 10pt; text-align: right">  —</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; width: 1%; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; width: 8%; padding-left: 10pt; text-align: right">  —</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; width: 1%">$</td> <td style="border-bottom: black 1pt solid; width: 8%; text-align: right">2,755,034</td> <td style="width: 1%; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-align: justify; text-indent: -10pt">The roll forward of the contingent consideration liability is as follows:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-indent: -10pt">Balance June 30, 2020</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3,182,434</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt">Contingent Shares issued pursuant to the Acquisition Agreement</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Fair value adjustment</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">—</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">—</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(427,400</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Balance September 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,755,034</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Useful Life</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> June 30, 2020</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 69%">Lab Equipment and Instruments</td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: center">4-7</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">534,527</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">534,527</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Leasehold Improvements</td> <td> </td> <td style="text-align: center">10</td> <td> </td> <td>$</td> <td style="text-align: right">224,629</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">224,629</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Furniture Fixtures and Equipment</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center">4-7</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">$</td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">171,975</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">171,975</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td>$</td> <td style="text-align: right">931,131</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">931,131</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Less Accumulated Depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">$</td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">(179,558</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(153,013</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Net Property and Equipment</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">751,573</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">778,118</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Below are the lease commitments for the next 5 years and thereafter:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Year Ending June 30th</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Lease Expense</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%; padding-left: 0.25in; text-indent: -9pt">2021</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">255,137</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.25in; text-indent: -9pt">2022</td> <td> </td> <td>$</td> <td style="text-align: right">348,495</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 0.25in; text-indent: -9pt">2023</td> <td> </td> <td>$</td> <td style="text-align: right">298,305</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.25in; text-indent: -9pt">2024</td> <td> </td> <td>$</td> <td style="text-align: right">246,004</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 0.25in; text-indent: -9pt">2025</td> <td> </td> <td>$</td> <td style="text-align: right">253,384</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.25in; text-indent: -9pt">Thereafter</td> <td> </td> <td>$</td> <td style="text-align: right">574,821</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt">Less imputed interest</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(238,535</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 0.5in; text-indent: -9pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,737,611</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

3.58

1.30

0.54

1438122

4977

15154

11241

3913

238535

12.00

1200000

188485

501370

493192

4654765

92313

2.69 3.26 3.84 3.85 3.95 4.12 4.63 4.8 4.85 4.9 5 5.74 5.8 6.15 6.25 6.5 1.30 8.00 6.95 7.1 8 P1Y9M3D P4M13D P1Y8M26D 20000000 Under the Purchase Agreement, we may direct Lincoln Park, at our sole discretion subject to certain conditions, to purchase up to 200,000 shares of Common Stock on any business day (a “Regular Purchase”). The amount of a Regular Purchase may be increased under certain circumstances up to 125,000 shares of Common Stock, provided that Lincoln Park’s committed obligation for Regular Purchases on any business day shall not exceed $1,000,000

2.00

1000000

4.42

0.0001

10000000

0.0001

100000000

46636976

46497409

1438122 1438122 1.42 1.42

326156

234010

89684

101521

Goodwill —Goodwill is not amortized but is evaluated for impairment annually as of June 30th or whenever events or changes in circumstances indicate the carrying value may not be recoverable.   We test for goodwill impairment at the reporting unit level, which is one level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of the reporting unit and is based on discounted cash flows or relative market-based approaches. If the fair value exceeds carrying value, then it is concluded that no goodwill impairment has occurred. If the carrying value of the reporting unit exceeds its fair value, a second step is required to measure possible goodwill impairment loss. The second step includes hypothetically valuing the tangible and intangible assets and liabilities of the reporting unit as if the reporting unit had been acquired in a business combination. Then, the implied fair value of the reporting unit’s goodwill is compared to the carrying value of that goodwill. If the carrying value of the reporting unit’s goodwill exceeds the implied fair value of the goodwill, we recognize an impairment loss in an amount equal to the excess, not to exceed the carrying value.   The carrying value of goodwill at September 30, 2020, was $11,640,000. We do not believe there is a reasonable likelihood that there will be a material change in the future estimates or assumptions we use to test for impairment losses on goodwill. However, if actual results are not consistent with our estimates or assumptions, we may be exposed to an impairment charge that could be material.

NOTE 6 — NOTES PAYABLE   Convertible Notes Payable   On February 6, 2020, the Company issued two Convertible Notes (the “Convertible Notes”) to an existing stockholder of the Company each with a face value amount of $600,000, convertible into shares of the Company’s Common Stock. The outstanding principal amount of the Convertible Notes is due and payable on February 6, 2023. Interest on the Convertible Notes commenced accruing on the date of issuance at six percent (6%) per annum, computed on the basis of twelve 30-day months, and is compounded monthly on the final day of each calendar month based upon the Principal and all accrued and unpaid Interest outstanding as of such compound date. The interest is payable in cash on a semi-annual basis.   The holder of the Convertible Notes has the right at any time prior to the date that is twelve months from issuance to convert all or any part of the outstanding and unpaid Principal and all unpaid Interest into shares of the Company’s Common Stock. The conversion price is equal to $12.00 per share of Common Stock. The Company evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded conversion feature that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily convertible into cash. All proceeds received from the issuance have been recognized as a liability on the balance sheet. The Convertible Notes balance as of September 30, 2020 and June 30, 2020, was $1,200,000.   Note Payable   On March 30, 2020 (the “Issuance Date”), the Company issued a Promissory Note in the principal amount of $5,000,000 (the “Unsecured Note”) to Paseco APS, a Danish limited company and an existing stockholder of the Company. The principal amount of the Note will be payable on November 30, 2021 (the “Maturity Date”) and bears interest at a fixed rate of 6% per annum, computed based on the number of days between the Issuance Date and the Maturity Date, which was prepaid by the Company in full on the Issuance Date through the issuance of 188,485 shares of the Company’s Common Stock based on the closing market price on that date for a total value of $501,370. The Company evaluated the Unsecured Note and PIK interest in accordance with ASC 470-Debt and ASC 835-Interest, respectively. Pursuant to ASC 470-20, proceeds received from the issuance are to be recognized at their relative fair value, thus the liability is shown net of the corresponding discount of $493,192, which is the relative fair value of the shares issued for the PIK interest on the closing date using the effective interest method. The discount will be accreted over the life of the Unsecured Note. The Note Payable balance, net of discount at September 30, 2020 is $4,654,765.   For the three months ended September 30, 2020, the Company recorded accrued interest and interest expense in the amount of $6,000, and $92,313, respectively. The interest expense includes $73,978 related to the amortization of the discount related to the Unsecured Note. These amounts are reflected in accrued expenses and general and administrative expenses.

NOTE 8 — COMMITMENTS AND CONTINGENCIES   Consulting Agreements –   On July 9, 2018, the Company entered into a consulting agreement with G-Tech Bio, LLC, a California limited liability company (“G-Tech”) to assist the Company with the development of the gene therapy and cell therapy modalities for the prevention, treatment, amelioration of HIV in humans, and with the development of a genetically enhanced Dendritic Cell for use as a wide spectrum platform for various diseases (including but not limited to cancers and infectious diseases) (the “G-Tech Agreement”). G-Tech was entitled to consulting fees for 20 months, with a monthly consulting fee of not greater than $130,000 per month. Upon the completion of the 20 months, the monthly consulting fee of $25,000 continued for scientific consulting and knowledge transfer on existing HIV experiments, and will continue until the services are no longer rendered or the agreement is terminated. G-Tech is controlled by certain members of Weird Science. For the three months ended September 30, 2020 and 2019, $50,000 and $375,000 was charged to research and development expenses in our Condensed Consolidated Statements of Operations related to this consulting agreement, respectively.   On January 31, 2020, the Company entered into a Statement of Work & License Agreement (the “HBV License Agreement”) by and among the Company, G Tech Bio, LLC, a California limited liability company (“G Tech”), and G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute (“SRI”), whereby the Company acquired a perpetual, sublicensable, exclusive license (the “HBV License”) for a treatment under development (the “Treatment”) aimed to treat Hepatitis B Virus (HBV) infections in accordance with its agreement in principle with G-Tech and SRI.   The HBV License Agreement states that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Treatment over a 24 month period, and provides for an up-front payment of $1.2 million within 7 days of January 31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides for cooperation related to the development of intellectual property related to the Treatment and for a 2% royalty to G Tech on any net sales that may occur under the HBV License. On February 6, 2020, the Company paid the $1.2 million aforementioned.   The cash funding for research costs and equipment pursuant to the HBV License Agreement consist of monthly payments amounting to $144,500 that cover scientific staffing resources to complete the project as well as periodic payments for materials and equipment needed to complete the project. During the three months ended September 30, 2020, the Company paid $433,500 for scientific staffing resources and $400,000 for mouse studies conducted by a collaborating partner.   The HBV License Agreement contains customary representations, warranties and covenants of the parties with respect to the development of the Treatment and the HBV License. G Tech and SRI are each controlled by certain members of Weird Science, LLC, a shareholder of the Company.   Shares held for non-consenting shareholders – The 77,249 remaining shares of Common Stock have been reflected as issued and outstanding in the accompanying financial statements. There were 4,988 shares of Common Stock issued to such non-consent shareholders during the three months ended September 30, 2020. (See Note 7)    Employment and Service Agreements  - The Company has an agreement with the Executive Vice-Chair, where he fulfills the duties as prescribed by the Company’s bylaws and receives annual compensation in the amount of $430,000, plus 300,000 options that vested immediately. Dr. Dybul was given a one-time grant of options to purchase 450,000 shares of Common Stock at a strike price of $8.00 per share on June 11, 2020. The Company executed a consulting agreement for services for a Senior Medical Advisor of $210,000 on a part-time basis. The Company maintains employment agreements with other staff in the ordinary course of business.   Contingencies – From time to time, the Company is involved in routine legal and administrative proceedings and claims of various types. While any proceedings or claim contains an element of uncertainty, management does not expect a material impact on our results of operations or financial position.

NOTE 4 —INTANGIBLE ASSETS   At September 30, 2020 and June 30, 2020, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company’s products and processes of $76,834 and $77,323, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense for the three months ended September 30, 2020 and 2019 was $3,913 and zero, respectively.   At September 30, 2020 and 2019, indefinite life intangibles assets consisted of a licenses agreements classified as In-Process Research and Development (“IPR&D”) intangible assets, which are not amortizable until the intangible asset provides economic benefit, and goodwill.   At September 30, 2020 and June 30, 2020, definite and indefinite-life intangible assets consisted of the following:    <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt; text-indent: -9pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Useful Life</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Period Change</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Effect of Currency Translation</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt; text-indent: -9pt">Definite Life Intangible Assets</td> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; padding-left: 18pt; text-indent: -9pt">Patents</td> <td style="width: 1%"> </td> <td style="width: 11%; padding-left: 5.4pt; text-align: center">20 Years</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">299,175</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">13,247</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">312,422</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 18pt; text-indent: -9pt">Less Accumulated Amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(221,852</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(3, 913</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(9,823</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(235,588</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 18pt; text-indent: -9pt">Net Definite-Life Intangible Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">77,323</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(3,913</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3,424</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">76,834</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"> </td> <td> </td> <td style="padding-left: 5.4pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt">Indefinite Life Intangible Assets</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 18pt; text-indent: -9pt">License Agreement</td> <td> </td> <td style="padding-left: 5.4pt"> </td> <td> </td> <td>$</td> <td style="text-align: right">154,824,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">154,824,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 18pt; text-indent: -9pt">Goodwill</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; padding-left: 5.4pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">11,640,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">11,640,000</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Total Indefinite Life Intangible Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">166,464,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">166,464,000</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Year ending September 30,</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%; padding-left: 18pt; text-indent: -9pt">2021</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">11,241</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 18pt; text-indent: -9pt">2022</td> <td> </td> <td>$</td> <td style="text-align: right">15,154</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 18pt; text-indent: -9pt">2023</td> <td> </td> <td>$</td> <td style="text-align: right">15,154</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 18pt; text-indent: -9pt">2024</td> <td> </td> <td>$</td> <td style="text-align: right">15,154</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 18pt; text-indent: -9pt">2025</td> <td> </td> <td>$</td> <td style="text-align: right">15,154</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 18pt; text-indent: -9pt">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">4,977</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 36pt; text-indent: -9pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">76,834</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   During February 2018, the Company acquired a License Agreement (as licensee) to the HIV therapy being developed as ENOB-HV-01 which consists of a perpetual, fully paid-up, royalty-free, sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. Because the HIV License Agreement is considered, an IPR&D intangible asset it is classified as an indefinite life asset that is tested annually for impairment.   Impairment – Following the fourth quarter of each year, management performs its annual test of impairment of intangible assets by performing a quantitative assessment and determines if it is more than likely than not that, the fair value of the asset is greater than or equal to the carrying value of the asset. The results of the quantitative assessment supported Management’s conclusion that an impairment adjustment was not required as of June 30, 2020.

NOTE 7 — STOCKHOLDERS’ EQUITY   Preferred Stock — The Company has 10,000,000 authorized shares of Preferred Stock, par value $0.0001 per share. At September 30, 2020, and June 30, 2020, there were zero shares issued and outstanding.   Common Stock — The Company has 100,000,000 authorized shares of Common Stock, par value $0.0001 per share. At September 30, 2020, and June 30, 2020, there were 46,636,976 and 46,497,409 shares issued and outstanding, respectively.   Voting — Holders of Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors.   Dividends — Holders of Common Stock are entitled to receive ratably such dividends as the Board from time to time may declare out of funds legally available.   Liquidation Rights — In the event of any liquidation, dissolution or winding-up of affairs of the Company, after payment of all of our debts and liabilities, the holders of Common Stock will be entitled to share ratably in the distribution of any of our remaining assets.   Purchase Agreement with Lincoln Park Capital   On July 8, 2020, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $20,000,000 of shares of our Common Stock from time to time from August 1, 2023.   Under the Purchase Agreement, we may direct Lincoln Park, at our sole discretion subject to certain conditions, to purchase up to 200,000 shares of Common Stock on any business day (a “Regular Purchase”). The amount of a Regular Purchase may be increased under certain circumstances up to 125,000 shares of Common Stock, provided that Lincoln Park’s committed obligation for Regular Purchases on any business day shall not exceed $1,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase price of shares of Common Stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the Purchase Agreement.   Our sale of shares of Common Stock to Lincoln Park subsequent to the Amendment Date is limited to 12,016,457 shares of Common Stock, representing 19.99% of the shares of the Common Stock outstanding on the Amendment Date unless (i) stockholder approval is obtained, (ii) the average price of all applicable sales to Lincoln Park under the Purchase Agreement equals or exceeds the lower of (A) the closing price of the Common Stock on the Nasdaq Capital Market immediately preceding the date of the Purchase Agreement or (B) the average of the closing prices on the Nasdaq Capital Market for the five Business Days immediately preceding the date of the Purchase Agreement or (ii) to the extent it would cause Lincoln Park to beneficially own more than 9.99% of the Company’s outstanding shares of Common Stock at any given time.    In consideration for entering into the Purchase Agreement, we issued 139,567 shares of Common Stock to Lincoln Park as a commitment fee on July 21, 2020.   During the three months ended September 30, 2020, we did not sell any shares of Common Stock to Lincoln Park under the Purchase Agreement.   Common Stock Issuances —    As of September 30, 2020, there were no other Common Stock issuances outside of the 139,567 shares of Common Stock issued to Lincoln Park as a commitment fee.   On July 3, 2019, the Registrant issued 500,000 shares of Common Stock valued at the price of $2.00 strike price per share pursuant to the exercise of vested options for total proceeds of $1.0 million.    On July 3, 2019, the Registrant issued 500,000 shares of Common Stock valued at the price of $4.42 per share in connection with the acquisition of Enochian Biopharma. This non-cash transaction impacted shareholders’ equity in the amount of $2.2 million.   Acquisition of Enochian Biopharma / Contingently issuable shares — On February 16, 2018, the Acquisition was completed when the subsidiary merged with and into Enochian Biopharma, with Enochian Biopharma as the surviving corporation. As consideration for the Acquisition, the stockholders of Enochian Biopharma received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive Contingent Shares pro rata upon the exercise or conversion of warrants, which were outstanding at closing. At September 30, 2020, 1,438,122 Contingent Shares are issuable in connection with the Acquisition of Enochian Biopharma.   Acquisition of Enochian Denmark —   At September 30, 2020 and June 30, 2020, the Company maintained a reserve of 77,249 and 82,237 shares of Common Stock of the Registrant held in escrow according to Danish law (the “Escrow Shares”), respectively, all of which are reflected as issued and outstanding in the accompanying financial statements. The Escrow Shares are reserved to acquire the shares of Enochian Denmark held by non-consenting shareholders of Enochian Denmark on both September 30, 2020 and June 30, 2020, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark. There have been 107,804 shares of Common Stock issued to non-consenting shareholders of Enochian Denmark as of September 30, 2020. During the three months ended September 30, 2020, the Company issued 4,988 shares of Common Stock to such non-consenting shareholders of Enochian Denmark, respectively. There is no impact on outstanding shares as these shares are reflected as issued and outstanding.    Recognition of Options   The Company recognizes compensation costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Enochian Biosciences Inc.</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 86%">Expected term (in years)</td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: center">5.5</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Volatility</td> <td> </td> <td style="text-align: center">79.92%-80.03%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk free interest rate</td> <td> </td> <td style="text-align: center">0.26%-.34%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Dividend yield</td> <td> </td> <td style="text-align: center">0%</td></tr> </table>   The Company recognized stock-based compensation expense related to the options of $316,950 and $226,266 for the three months ended September 30, 2020 and year ended 2019, respectively. At September 30, 2020, the Company had approximately $836,754 of unrecognized compensation cost related to non-vested options.   Plan Options   On February 6, 2014, the Board adopted the Company’s 2014 Equity Incentive Plan (the “Plan”), and the Company had reserved 1,206,000 shares of Common Stock for issuance in accordance with the terms of the Plan.   On October 30, 2019, the Board approved and on October 31, 2019, the Company’s shareholders adopted the Enochian’s 2019 Equity Incentive Plan (the “2019 Plan”), which replaced the 2014 Plan. The 2019 Plan authorized options to be awarded to not exceed the sum of (1) 6,000,000 new shares of Common Stock, and (2) the number of shares of Common Stock available for the grant of awards as of the effective date under the 2014 Plan that, after the effective date of the 2019 Plan, expires, or is terminated, surrendered, or forfeited for any reason without issuance of shares. The remaining shares of Common Stock available for grant related to the 2014 Plan was of 655,769 as of the effective date, this amount along with the new 6,000,000 shares totals 6,655,769 shares of Common Stock available to grant immediately after the effective date of the 2019 Plan.   For the three months ended September 30, 2020, the Company granted annual options to purchase 24,196 shares of Common Stock to members of the Board of Directors and Scientific Advisory Board with a one-year vesting period. Options will be exercisable at the market price of the Company’s Common Stock on the date of the grant.   For the three months ended September 30, 2019, the Company granted annual options of 13,470 to members of the Board of Directors and Scientific Advisory Board with a one-year vesting period pursuant to their contracts, and granted 20,000 fully vested options to senior employees in pursuant to the 2014 Plan. Options will be exercisable at the market price of the Companys common stock on the date of the grant.   To date the Company has granted options under the 2019 Plan (“Plan Options”) to purchase 1,129,638 shares of Common Stock.   A summary of the status of the Plan Options and Grant Warrants outstanding at September 30, 2020 is presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: black 1pt solid; text-align: center">Options Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center">Options Exercisable</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Prices</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (years)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number Exercisable</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (years)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 12%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2.69</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">55,762</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">9.44</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2.69</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">—</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.26</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">23,006</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.42</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.26</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.84</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,719</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.84</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.84</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.85</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,195</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.84</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.85</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,063</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7.84</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,063</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7.84</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.95</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.12</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,282</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.80</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.12</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.63</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.63</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.63</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,749</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.25</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.85</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,124</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,124</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.90</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,183</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.86</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.90</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,183</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.86</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.90</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.74</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,679</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7.97</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.74</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,679</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7.97</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.74</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,759</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.03</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,759</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.03</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.80</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.15</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">60,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.69</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.15</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">20,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.69</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.15</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">24,001</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.44</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">24,001</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.44</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.25</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">300,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.15</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">300,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.15</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.50</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,317</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.53</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,317</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.53</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.95</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">7.10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,563</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.42</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">7.10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,563</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.42</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">7.10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">8.00</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">519,235</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">9.42</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">8.00</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">55,695</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7.60</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">8.00</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,129,638</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8.96</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.72</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">472,385</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8.17</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.50</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   A summary of the status of the Plan Options at September 30, 2020 and changes since July 1, 2020 are presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Life</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Intrinsic Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%">Outstanding at beginning of period</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">1,105,442</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">6.78</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">9.19</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">107,931</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">24,196</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.93</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10.0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Outstanding at end of period</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,129,638</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">6.72</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">8.96</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">56,990</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Vested and expected to vest</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Exercisable end of period</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">472,385</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.50</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8.17</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   At September 30, 2020, the Company had 472,385 exercisable Plan Options. The total intrinsic value of options at September 30, 2020 is zero.  Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) at September 30, 2020 (for outstanding options), less the applicable exercise price.     Common Stock Purchase Warrants   A summary of the shares of Common Stock, which can be purchased related to the underlying the warrants outstanding for the three-month period as of September 30, 2020, is presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Life</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%">Outstanding at beginning of period</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">1,438,122</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">1.42</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">1.74</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted    </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised    </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Cancelled/Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Outstanding at end of period</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,438,122</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1.42</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1.74</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Exercisable end of period  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,438,122</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.42</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.74</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Equivalent Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Underlying Warrants</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Equivalent Shares Exercisable</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Prices</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Equivalent Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weight Average Remaining Contractual Life (years)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weight Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number Exercisable</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1.30</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">1,413,122</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">1.76</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1.30</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">1,413,122</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">1.30</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">8.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">.37</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">8.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">8.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="2" style="border-bottom: black 2.25pt double">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,438,122</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.74</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.42</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,438,122</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.42</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The exercise price of certain warrants and the number of shares underlying the warrants are subject to adjustment for stock dividends, subdivisions of the outstanding shares of Common Stock and combinations of the outstanding shares of Common Stock. For so long as the warrants remain outstanding, we are required to keep reserved from our authorized and unissued shares of Common Stock a sufficient number of shares to provide for the issuance of the shares underlying the warrants.   Restricted Stock Units (RSUs)   The Company recognized stock-based compensation expense related to the RSUs of $9,206 and $7,744 for the three months ended September 30, 2020 and 2019, respectively    A summary of the status of Restricted Stock Units outstanding at September 30, 2020 is presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Issuance Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Life</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Intrinsic Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%">Outstanding at beginning of period</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">10,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">6.15</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">.77</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">—</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td>$</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td>$</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cancelled/Expired</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td>$</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Outstanding at end of period</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">10,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">6.15</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">.77</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Exercisable end of period</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Restricted Stock Units Outstanding</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Grant Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Stock Units</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weight Average Remaining Contractual Life (years)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weight Average Issuance Price</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid; width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 23%; text-align: right">6.15</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 22%; text-align: right">10,000</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 22%; text-align: right">.77</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; width: 1%">$</td> <td style="border-bottom: black 1pt solid; width: 22%; text-align: right">6.15</td> <td style="width: 1%; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="2" style="border-bottom: black 2.25pt double">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">10,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">.77</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.15</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

At September 30, 2020 and June 30, 2020, definite and indefinite-life intangible assets consisted of the following:    <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt; text-indent: -9pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Useful Life</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Period Change</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Effect of Currency Translation</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt; text-indent: -9pt">Definite Life Intangible Assets</td> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; padding-left: 18pt; text-indent: -9pt">Patents</td> <td style="width: 1%"> </td> <td style="width: 11%; padding-left: 5.4pt; text-align: center">20 Years</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">299,175</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">13,247</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">312,422</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 18pt; text-indent: -9pt">Less Accumulated Amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(221,852</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(3, 913</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(9,823</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(235,588</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 18pt; text-indent: -9pt">Net Definite-Life Intangible Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">77,323</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(3,913</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3,424</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">76,834</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"> </td> <td> </td> <td style="padding-left: 5.4pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt">Indefinite Life Intangible Assets</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 18pt; text-indent: -9pt">License Agreement</td> <td> </td> <td style="padding-left: 5.4pt"> </td> <td> </td> <td>$</td> <td style="text-align: right">154,824,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">154,824,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 18pt; text-indent: -9pt">Goodwill</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; padding-left: 5.4pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">11,640,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">11,640,000</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Total Indefinite Life Intangible Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">166,464,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">166,464,000</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Year ending September 30,</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%; padding-left: 18pt; text-indent: -9pt">2021</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">11,241</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 18pt; text-indent: -9pt">2022</td> <td> </td> <td>$</td> <td style="text-align: right">15,154</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 18pt; text-indent: -9pt">2023</td> <td> </td> <td>$</td> <td style="text-align: right">15,154</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 18pt; text-indent: -9pt">2024</td> <td> </td> <td>$</td> <td style="text-align: right">15,154</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 18pt; text-indent: -9pt">2025</td> <td> </td> <td>$</td> <td style="text-align: right">15,154</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 18pt; text-indent: -9pt">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">4,977</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 36pt; text-indent: -9pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">76,834</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The weighted-average assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Enochian Biosciences Inc.</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 86%">Expected term (in years)</td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: center">5.5</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Volatility</td> <td> </td> <td style="text-align: center">79.92%-80.03%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk free interest rate</td> <td> </td> <td style="text-align: center">0.26%-.34%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Dividend yield</td> <td> </td> <td style="text-align: center">0%</td></tr> </table>

A summary of the status of the Plan Options and Grant Warrants outstanding at September 30, 2020 is presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: black 1pt solid; text-align: center">Options Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center">Options Exercisable</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Prices</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (years)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number Exercisable</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (years)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 12%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2.69</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">55,762</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">9.44</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2.69</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">—</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.26</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">23,006</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.42</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.26</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.84</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,719</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.84</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.84</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.85</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,195</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.84</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.85</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,063</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7.84</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,063</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7.84</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.95</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.12</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,282</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.80</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.12</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.63</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.63</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.63</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,749</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.25</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.85</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,124</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,124</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.90</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,183</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.86</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.90</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,183</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.86</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.90</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.74</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,679</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7.97</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.74</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,679</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7.97</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.74</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,759</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.03</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,759</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.03</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.80</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.15</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">60,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.69</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.15</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">20,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.69</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.15</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">24,001</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.44</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">24,001</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.44</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.25</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">300,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.15</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">300,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.15</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.50</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,317</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.53</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,317</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.53</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">6.95</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">7.10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,563</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.42</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">7.10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,563</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.42</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">7.10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">8.00</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">519,235</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">9.42</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">8.00</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">55,695</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7.60</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">8.00</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,129,638</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8.96</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.72</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">472,385</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8.17</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.50</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the status of the Plan Options at September 30, 2020 and changes since July 1, 2020 are presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Life</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Intrinsic Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%">Outstanding at beginning of period</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">1,105,442</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">6.78</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">9.19</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">107,931</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">24,196</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">3.93</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10.0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Outstanding at end of period</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,129,638</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">6.72</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">8.96</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">56,990</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Vested and expected to vest</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Exercisable end of period</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">472,385</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.50</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8.17</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the shares of Common Stock, which can be purchased related to the underlying the warrants outstanding for the three-month period as of September 30, 2020, is presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Life</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%">Outstanding at beginning of period</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">1,438,122</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">1.42</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">1.74</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted    </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised    </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Cancelled/Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Outstanding at end of period</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,438,122</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1.42</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1.74</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Exercisable end of period  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,438,122</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.42</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.74</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Equivalent Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Underlying Warrants</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Equivalent Shares Exercisable</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Prices</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Equivalent Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weight Average Remaining Contractual Life (years)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weight Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number Exercisable</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1.30</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">1,413,122</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">1.76</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1.30</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">1,413,122</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">1.30</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">8.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">.37</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">8.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">8.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="2" style="border-bottom: black 2.25pt double">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,438,122</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.74</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.42</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,438,122</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.42</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the status of Restricted Stock Units outstanding at September 30, 2020 is presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Issuance Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Life</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Intrinsic Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%">Outstanding at beginning of period</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">10,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">6.15</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">.77</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">—</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td>$</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td>$</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cancelled/Expired</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td>$</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Outstanding at end of period</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">10,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">6.15</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">.77</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Exercisable end of period</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

EX-101.SCH 7 enob-20200930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - FAIR VALUE MEASUREMENT link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - FAIR VALUE MEASUREMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - FAIR VALUE MEASUREMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - INTANGIBLE ASSETS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - STOCKHOLDERS' EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - STOCKHOLDERS' EQUITY (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - STOCKHOLDERS' EQUITY (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - STOCKHOLDERS' EQUITY (Details 5) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details 6) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 enob-20200930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 enob-20200930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 enob-20200930_lab.xml XBRL LABEL FILE Income Statement Location [Axis] General and Administrative Expense [Member] Transactions [Axis] Agreement and Plan of Merger (the "Acquisition Agreement") [Member] Business Acquisition [Axis] Enochian Biopharma Inc. and Weird Science LLC [Member] Property, Plant and Equipment, Type [Axis] Lab equipment and instruments [Member] Range [Axis] Minimum [Member] Maximum [Member] Leasehold improvements [Member] Furniture fixtures and equipment [Member] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization [Member] Patents [Member] Licensing Agreements [Member] Goodwill [Member] Legal Entity [Axis] Enochian Biosciences [Member] Option Indexed to Issuer's Equity [Axis] Employee Stock Option [Member] Common Stock Purchase Warrants [Member] Award Type [Axis] Employee Stock Option [Member] Exercise Price Range [Axis] Exercise Price Range 6.15 [Member] 2019 Equity Incentive Plan [Member] 2014 Equity Incentive Plan [Member] Related Party [Axis] DanDrit Denmark [Member] Consulting Agreement [Axis] Consulting Agreement [Member] G-Tech[Member] License Agreement Long-term Debt, Type [Axis] Note Payable [Member] Convertible Notes Payable [Member] Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Income Acquisition of Enochian Biopharma [Member] Exercise Price Range 2.69 [Member] Exercise Price Range 3.26 [Member] Exercise Price Range 3.84 [Member] Exercise Price Range 3.85 [Member] Exercise Price Range 3.95 [Member] Exercise Price Range 4.12 [Member] Exercise Price Range 4.63 [Member] Exercise Price Range 4.80 [Member] Exercise Price Range 4.85 [Member] Exercise Price Range 4.90 [Member] Exercise Price Range 5.00 [Member] Exercise Price Range 5.74 [Member] Exercise Price Range 5.80 [Member] Exercise Price Range 6.25 [Member] Exercise Price Range 6.50 [Member] Warrant [Member] Exercise Price Range 1.30 [Member] Exercise Price Range 8.00 [Member] Lincoln Park [Member] Purchase Agreement [Member] Stock Option [Member] Board of Directors [Member] Senior Employees [Member] Exercise Price Range 6.95 [Member] Exercise Price Range 7.10 [Member] Exercise Price Range 8.00 [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity Current Reporting Status Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Shell Company Entity File Number Entity Incorporation, State or Country Code Entity Interactive Data Current Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets: Cash Other receivables Prepaid expenses Total Current Assets Property and equipment, net OTHER ASSETS Definite life intangible assets, net Indefinite life intangible assets Goodwill Deposits and other assets Right of use assets Total Other Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable - trade Accrued Expenses Current portion of operating lease liabilities Total Current Liabilities NON-CURRENT LIABILITIES: Contingent consideration liability Lease liabilities, non-current Convertible Notes Payable-LT Notes payable - LT, net of discount Total Liabilities Commitments and Contingencies STOCKHOLDERS' EQUITY : Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding Common stock, par value $0.0001, 100,000,000 shares authorized, 46,636,976 shares issued and outstanding at September 30, 2020; 46,497,409 shares issued and outstanding at June 30, 2020 Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Total Stockholders' Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common Stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of Goods Sold Gross profit (Loss) Operating Expenses General and administrative Research and development Depreciation and amortization Total Operating Expense LOSS FROM OPERATIONS Other Income (Expense) Change in fair value of contingent consideration Interest income (expense) Gain (loss) on currency transactions Interest and other income Total Other Income (Expense) Loss Before Income Taxes Income Tax Benefit NET LOSS BASIC AND DILUTED LOSS PER SHARE WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED Statement of Comprehensive Income [Abstract] Net Loss Foreign Currency Translation, Adjustments Other Comprehensive Loss Statement [Table] Statement [Line Items] Beginning Balance, Value Beginning Balance, Shares Issuance of commitment shares, Value Issuance of commitment shares, Shares Stock issued pursuant to warrants exercised, Value Stock issued pursuant to warrants exercised, Shares Contingent Share issued pursuant to Acquisition Agreement, Value Contingent Share issued pursuant to Acquisition Agreement, Shares Stock-based compensation Foreign Currency Translation Adjustment Ending Balance, Value Ending Balance, Shares Statement of Cash Flows [Abstract] NET LOSS ADJUSTMENT TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES: Depreciation and amortization Change in contingent consideration liability Stock Based Compensation Expense ROU assets Amortization of Discount of Notes Payable CHANGES IN ASSETS AND LIABILITIES: Other Receivables Prepaid Expenses/Deposits Accounts Payable Accrued Expenses Operating Lease Liabilities NET CASH USED IN OPERATINGACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment NET CASH USED IN INVESTING ACTIVITIES EX-101.PRE 11 enob-20200930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Nov. 12, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	Enochian Biosciences Inc
Entity Central Index Key	0001527728
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity File Number	001-38758
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		46,636,976
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Current Assets:
Cash	$ 5,965,661	$ 8,696,361
Other receivables		1,982
Prepaid expenses	99,872	242,866
Total Current Assets	6,065,533	8,941,209
Property and equipment, net	751,573	778,118
OTHER ASSETS
Definite life intangible assets, net	76,834	77,323
Indefinite life intangible assets	154,824,000	154,824,000
Goodwill	11,640,000	11,640,000
Deposits and other assets	137,550	137,550
Right of use assets	1,637,878	1,703,859
Total Other Assets	168,316,262	168,382,732
TOTAL ASSETS	175,133,368	178,102,059
CURRENT LIABILITIES:
Accounts payable - trade	282,376	592,877
Accrued Expenses	273,345	470,636
Current portion of operating lease liabilities	276,456	271,285
Total Current Liabilities	832,177	1,334,798
NON-CURRENT LIABILITIES:
Contingent consideration liability	2,755,034	3,182,434
Lease liabilities, non-current	1,461,156	1,531,779
Convertible Notes Payable-LT	1,200,000	1,200,000
Notes payable - LT, net of discount	4,654,765	4,580,787
Total Liabilities	10,903,132	11,829,798
Commitments and Contingencies
STOCKHOLDERS' EQUITY :
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, par value $0.0001, 100,000,000 shares authorized, 46,636,976 shares issued and outstanding at September 30, 2020; 46,497,409 shares issued and outstanding at June 30, 2020	4,664	4,650
Additional paid-in capital	230,823,367	230,497,225
Accumulated deficit	(66,584,768)	(64,188,198)
Accumulated other comprehensive loss	(13,027)	(41,416)
Total Stockholders' Equity	164,230,236	166,272,261
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 175,133,368	$ 178,102,059

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2020	Jun. 30, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	46,636,976	46,497,409
Common stock, shares outstanding	46,636,976	46,497,409

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenues
Cost of Goods Sold
Gross profit (Loss)
Operating Expenses
General and administrative	1,777,923	1,900,812
Research and development	1,050,376	520,192
Depreciation and amortization	30,458	21,481
Total Operating Expense	2,858,757	2,442,485
LOSS FROM OPERATIONS	(2,858,757)	(2,442,485)
Other Income (Expense)
Change in fair value of contingent consideration	427,400	(1,942,000)
Interest income (expense)	(92,313)
Gain (loss) on currency transactions		286,755
Interest and other income	4,306	14,553
Total Other Income (Expense)	339,393	(1,640,692)
Loss Before Income Taxes	(2,519,365)	(4,083,177)
Income Tax Benefit	122,794
NET LOSS	$ (2,396,570)	$ (4,083,177)
BASIC AND DILUTED LOSS PER SHARE	$ (0.05)	$ (0.09)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED	46,605,118	46,241,315

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net Loss	$ (2,396,570)	$ (4,083,177)
Foreign Currency Translation, Adjustments	28,389	(278,656)
Other Comprehensive Loss	$ (2,368,181)	$ (4,361,833)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Beginning Balance, Value at Jun. 30, 2019	$ 4,527	$ 225,765,432	$ (52,771,840)	$ 101,818	$ 173,099,937
Beginning Balance, Shares at Jun. 30, 2019	45,273,924
Stock issued pursuant to warrants exercised, Value	$ 50	999,950			1,000,000
Stock issued pursuant to warrants exercised, Shares	500,000
Contingent Share issued pursuant to Acquisition Agreement, Value	$ 50	2,209,950			2,210,000
Contingent Share issued pursuant to Acquisition Agreement, Shares	500,000
Stock-based compensation		234,010			234,010
Net Loss			(4,083,177)		(4,083,177)
Foreign Currency Translation Adjustment				(278,656)	(278,656)
Ending Balance, Value at Sep. 30, 2019	$ 4,627	229,209,342	(56,855,017)	(176,838)	172,182,114
Ending Balance, Shares at Sep. 30, 2019	46,273,924
Beginning Balance, Value at Jun. 30, 2020	$ 4,650	230,497,225	(64,188,198)	(41,416)	166,272,261
Beginning Balance, Shares at Jun. 30, 2020	46,497,409
Issuance of commitment shares, Value	$ 14	(14)
Issuance of commitment shares, Shares	139,567
Stock-based compensation		326,156			326,156
Net Loss			(2,396,570)		(2,396,570)
Foreign Currency Translation Adjustment				28,389	28,389
Ending Balance, Value at Sep. 30, 2020	$ 4,664	$ 230,823,367	$ (66,584,768)	$ (13,027)	$ 164,230,236
Ending Balance, Shares at Sep. 30, 2020	46,636,976

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Statement of Cash Flows [Abstract]
NET LOSS	$ (2,396,570)	$ (4,083,177)
ADJUSTMENT TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation and amortization	30,458	21,481
Change in contingent consideration liability	(427,400)	1,942,000
Stock Based Compensation Expense	326,156	234,010
ROU assets	65,981	68,866
Amortization of Discount of Notes Payable	73,978
CHANGES IN ASSETS AND LIABILITIES:
Other Receivables	1,982	6,098
Prepaid Expenses/Deposits	142,994	135,793
Accounts Payable	(310,501)	71,022
Accrued Expenses	(197,291)	(136,424)
Operating Lease Liabilities	(65,452)	(60,256)
NET CASH USED IN OPERATINGACTIVITIES	(2,755,665)	(1,800,587)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(68,616)
NET CASH USED IN INVESTING ACTIVITIES		(68,616)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants		1,000,000
NET CASH PROVIDED BY FINANCING ACTIVITIES		1,000,000
(Loss) on Currency Translation	24,965	(274,769)
NET CHANGE IN CASH	(2,730,700)	(1,143,972)
CASH, BEGINNING OF PERIOD	8,696,361	12,282,224
CASH, END OF PERIOD	5,965,661	11,138,252
Cash paid during the quarter end for:
Interest	42,365
Income Taxes	37
Non-cash operating, investing and financing Activities:
Contingent Shares issued in connection with Acquisition Agreement		$ 2,210,000

XML 19 R8.htm IDEA: XBRL DOCUMENT

THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Intangible Assets - The Company has both Definite and Indefinite life intangible assets.

Goodwill —Goodwill is not amortized but is evaluated for impairment annually as of June 30^th or whenever events or changes in circumstances indicate the carrying value may not be recoverable.

●

Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Recent Adopted Accounting Pronouncements

The Company adopted ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements, as of July 1, 2020 (Note 2).

Other recent accounting pronouncements issued by the FASB do not or are not believed by management to have a material impact on the Company’s present or future financial statements.

XML 20 R9.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENT

3 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

FAIR VALUE MEASUREMENT

●

Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The were no Level 1, 2 or 3 assets, nor and Level 1 or 2 liabilities as of September 30, 2020.

	Fair Value Measurements at Reporting Date Using
	Quoted Prices in Active Markets for Identical Assets Inputs		Significant Other Observable Inputs		Significant Other Unobservable
	(Level 1)		(Level 2)		(Level 3)
Contingent Consideration Liability		—		—	$	2,755,034
The roll forward of the contingent consideration liability is as follows:
Balance June 30, 2020		—		—	$	3,182,434
Contingent Shares issued pursuant to the Acquisition Agreement		—		—	$	—
Fair value adjustment		—		—	$	(427,400	)
Balance September 30, 2020		—		—	$	2,755,034

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT

3 Months Ended

Sep. 30, 2020

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 3 — PROPERTY AND EQUIPMENT

	Useful Life	September 30, 2020			June 30, 2020
Lab Equipment and Instruments	4-7	$	534,527		$	534,527
Leasehold Improvements	10	$	224,629			224,629
Furniture Fixtures and Equipment	4-7	$	171,975		$	171,975
Total		$	931,131		$	931,131
Less Accumulated Depreciation		$	(179,558	)	$	(153,013	)
Net Property and Equipment		$	751,573		$	778,118

During the three months ended September 30, 2020, and 2019, respectively, the Company had depreciation expense of $26,545, and $21,481, respectively.

XML 22 R11.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS

3 Months Ended

Sep. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 4 —INTANGIBLE ASSETS

At September 30, 2020 and June 30, 2020, definite and indefinite-life intangible assets consisted of the following:

	Useful Life	June 30, 2020			Period Change			Effect of Currency Translation			September 30, 2020
Definite Life Intangible Assets
Patents	20 Years	$	299,175		$				13,247			312,422
Less Accumulated Amortization		$	(221,852	)	$	(3, 913	)		(9,823	)		(235,588	)
Net Definite-Life Intangible Assets		$	77,323		$	(3,913	)		3,424			76,834

Indefinite Life Intangible Assets
License Agreement		$	154,824,000								$	154,824,000
Goodwill		$	11,640,000								$	11,640,000
Total Indefinite Life Intangible Assets		$	166,464,000								$	166,464,000

Year ending September 30,
2021	$	11,241
2022	$	15,154
2023	$	15,154
2024	$	15,154
2025	$	15,154
Thereafter	$	4,977
Total	$	76,834

XML 23 R12.htm IDEA: XBRL DOCUMENT

LEASES

3 Months Ended

Sep. 30, 2020

Leases [Abstract]

LEASES

NOTE 5 — LEASES

The Company identified and assessed the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities:

For the three months ended September 30, 2020, and September 30, 2019, lease expense charged to general and administrative expenses amounted to $89,684 and $101,521, respectively.

Below are the lease commitments for the next 5 years and thereafter:

Year Ending June 30^th	Lease Expense
2021	$	255,137
2022	$	348,495
2023	$	298,305
2024	$	246,004
2025	$	253,384
Thereafter	$	574,821
Less imputed interest		(238,535	)
Total	$	1,737,611

XML 24 R13.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

3 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

NOTES PAYABLE

NOTE 6 — NOTES PAYABLE

Convertible Notes Payable

Note Payable

XML 25 R14.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

3 Months Ended

Sep. 30, 2020

Stockholders' Equity Note [Abstract]

STOCKHOLDERS' EQUITY

NOTE 7 — STOCKHOLDERS’ EQUITY

Dividends — Holders of Common Stock are entitled to receive ratably such dividends as the Board from time to time may declare out of funds legally available.

Purchase Agreement with Lincoln Park Capital

In consideration for entering into the Purchase Agreement, we issued 139,567 shares of Common Stock to Lincoln Park as a commitment fee on July 21, 2020.

During the three months ended September 30, 2020, we did not sell any shares of Common Stock to Lincoln Park under the Purchase Agreement.

Common Stock Issuances —

As of September 30, 2020, there were no other Common Stock issuances outside of the 139,567 shares of Common Stock issued to Lincoln Park as a commitment fee.

Recognition of Options

		Enochian Biosciences Inc.
Expected term (in years)		5.5
Volatility		79.92%-80.03%
Risk free interest rate		0.26%-.34%
Dividend yield		0%

Plan Options

To date the Company has granted options under the 2019 Plan (“Plan Options”) to purchase 1,129,638 shares of Common Stock.

A summary of the status of the Plan Options and Grant Warrants outstanding at September 30, 2020 is presented below:

Options Outstanding							Options Exercisable
	Exercise Prices		Number Outstanding		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price
	$	2.69		55,762		9.44	$	2.69		—		—	$	—
	$	3.26		23,006		9.42	$	3.26		—		—	$	—
	$	3.84		11,719		9.84	$	3.84		—		—	$	—
	$	3.85		5,195		9.84	$	3.85		—		—	$	—
	$	3.95		5,063		7.84	$	3.95		5,063		7.84	$	3.95
	$	4.12		7,282		9.80	$	4.12		—		—	$	—
	$	4.63		10,000		8.90	$	4.63		10,000		8.90	$	4.63
	$	4.80		50,749		9.25	$	4.80		—		—	$	—
	$	4.85		4,124		8.90	$	5.00		4,124		8.90	$	5.00
	$	4.90		9,183		8.86	$	4.90		9,183		8.86	$	4.90
	$	5.00		6,000		8.90	$	5.00		6000		—	$	5.00
	$	5.74		15,679		7.97	$	5.74		15,679		7.97	$	5.74
	$	5.80		7,759		8.03	$	5.80		7,759		8.03	$	5.80
	$	6.15		60,000		8.69	$	6.15		20,000		8.69	$	6.15
	$	6.25		24,001		8.44	$	6.25		24,001		8.44	$	6.25
	$	6.50		300,000		8.15	$	6.50		300,000		8.15	$	6.50
	$	6.95		4,317		8.53	$	6.95		4,317		8.53	$	6.95
	$	7.10		10,563		8.42	$	7.10		10,563		8.42	$	7.10
	$	8.00		519,235		9.42	$	8.00		55,695		7.60	$	8.00
Total	$	—		1,129,638		8.96	$	6.72		472,385		8.17	$	6.50

A summary of the status of the Plan Options at September 30, 2020 and changes since July 1, 2020 are presented below:

			Weighted Average		Average		Weighted Average
	Shares		Exercise Price		Remaining Life		Intrinsic Value

Outstanding at beginning of period		1,105,442	$	6.78		9.19	$	107,931
Granted		24,196	$	3.93		10.0		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
Outstanding at end of period		1,129,638	$	6.72		8.96	$	56,990
Vested and expected to vest								-
Exercisable end of period		472,385	$	6.50		8.17	$	-

Common Stock Purchase Warrants

A summary of the shares of Common Stock, which can be purchased related to the underlying the warrants outstanding for the three-month period as of September 30, 2020, is presented below:

			Weighted Average		Weighted Average
	Shares		Exercise Price		Remaining Life

Outstanding at beginning of period		1,438,122	$	1.42		1.74
Granted
Exercised		-		-		-
Cancelled/Expired		-		-		-
Outstanding at end of period		1,438,122	$	1.42		1.74
Exercisable end of period		1,438,122	$	1.42		1.74

		Equivalent Shares		Underlying Warrants		Outstanding		Equivalent Shares Exercisable
Exercise Prices		Equivalent Shares		Weight Average Remaining Contractual Life (years)		Weight Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	1.30		1,413,122		1.76	$	1.30		1,413,122	$	1.30
$	8.00		25,000		.37	$	8.00		25,000	$	8.00

Total			1,438,122		1.74	$	1.42		1,438,122	$	1.42

Restricted Stock Units (RSUs)

The Company recognized stock-based compensation expense related to the RSUs of $9,206 and $7,744 for the three months ended September 30, 2020 and 2019, respectively

A summary of the status of Restricted Stock Units outstanding at September 30, 2020 is presented below:

			Weighted Average		Weighted Average		Weighted Average
	Shares		Issuance Price		Remaining Life		Intrinsic Value

Outstanding at beginning of period		10,000	$	6.15		.77	$	—
Granted			$				$	—
Exercised			$
Cancelled/Expired			$				$	—
Outstanding at end of period		10,000	$	6.15		.77	$	—
Exercisable end of period		—	$	—		—	$	—

		Restricted Stock Units Outstanding
Grant Price		Stock Units		Weight Average Remaining Contractual Life (years)		Weight Average Issuance Price
	6.15		10,000		.77	$	6.15
Total			10,000		.77	$	6.15

XML 26 R15.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 8 — COMMITMENTS AND CONTINGENCIES

Consulting Agreements –

XML 27 R16.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Sep. 30, 2020

RELATED PARTY TRANSACTIONS

NOTE 9 — RELATED PARTY TRANSACTIONS

On January 31, 2020, the Company entered into the HBV License Agreement by and among the Company, G Tech and SRI, whereby the Company acquired the HBV License for the Treatment. (See Note 8)

XML 28 R17.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Sep. 30, 2020

Subsequent Events [Abstract]

SUBSEQUENT EVENT

NOTE 10 — SUBSEQUENT EVENTS

XML 29 R18.htm IDEA: XBRL DOCUMENT

THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Business

Basis of Presentation

Functional Currency & Foreign currency translation

Cash and Cash Equivalents

Property and Equipment

Intangible Assets

Intangible Assets - The Company has both Definite and Indefinite life intangible assets.

Goodwill

Goodwill —Goodwill is not amortized but is evaluated for impairment annually as of June 30^th or whenever events or changes in circumstances indicate the carrying value may not be recoverable.

Impairment of Long-Lived Assets

Leases

Research and Development Expenses

Income Taxes

Loss Per Share

Fair Value of Financial Instruments

●

Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Stock Options and Restricted Share Units

Stock-Based Compensation

Recent Adopted Accounting Pronouncements

Recent Adopted Accounting Pronouncements

The Company adopted ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements, as of July 1, 2020 (Note 2).

Other recent accounting pronouncements issued by the FASB do not or are not believed by management to have a material impact on the Company’s present or future financial statements.

XML 30 R19.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENT (Tables)

3 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Summary of significant to the fair value measurement

	Fair Value Measurements at Reporting Date Using
	Quoted Prices in Active Markets for Identical Assets Inputs		Significant Other Observable Inputs		Significant Other Unobservable
	(Level 1)		(Level 2)		(Level 3)
Contingent Consideration Liability		—		—	$	2,755,034
The roll forward of the contingent consideration liability is as follows:
Balance June 30, 2020		—		—	$	3,182,434
Contingent Shares issued pursuant to the Acquisition Agreement		—		—	$	—
Fair value adjustment		—		—	$	(427,400	)
Balance September 30, 2020		—		—	$	2,755,034

XML 31 R20.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Sep. 30, 2020

Property, Plant and Equipment [Abstract]

Summary of property and equipment

	Useful Life	September 30, 2020			June 30, 2020
Lab Equipment and Instruments	4-7	$	534,527		$	534,527
Leasehold Improvements	10	$	224,629			224,629
Furniture Fixtures and Equipment	4-7	$	171,975		$	171,975
Total		$	931,131		$	931,131
Less Accumulated Depreciation		$	(179,558	)	$	(153,013	)
Net Property and Equipment		$	751,573		$	778,118

XML 32 R21.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

3 Months Ended

Sep. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of life intangible assets

At September 30, 2020 and June 30, 2020, definite and indefinite-life intangible assets consisted of the following:

	Useful Life	June 30, 2020			Period Change			Effect of Currency Translation			September 30, 2020
Definite Life Intangible Assets
Patents	20 Years	$	299,175		$				13,247			312,422
Less Accumulated Amortization		$	(221,852	)	$	(3, 913	)		(9,823	)		(235,588	)
Net Definite-Life Intangible Assets		$	77,323		$	(3,913	)		3,424			76,834

Indefinite Life Intangible Assets
License Agreement		$	154,824,000								$	154,824,000
Goodwill		$	11,640,000								$	11,640,000
Total Indefinite Life Intangible Assets		$	166,464,000								$	166,464,000

Schedule of expected future amortization expense

Year ending September 30,
2021	$	11,241
2022	$	15,154
2023	$	15,154
2024	$	15,154
2025	$	15,154
Thereafter	$	4,977
Total	$	76,834

XML 33 R22.htm IDEA: XBRL DOCUMENT

LEASES (Tables)

3 Months Ended

Sep. 30, 2020

Leases [Abstract]

Lease commitments

Below are the lease commitments for the next 5 years and thereafter:

Year Ending June 30^th	Lease Expense
2021	$	255,137
2022	$	348,495
2023	$	298,305
2024	$	246,004
2025	$	253,384
Thereafter	$	574,821
Less imputed interest		(238,535	)
Total	$	1,737,611

XML 34 R23.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

3 Months Ended

Sep. 30, 2020

Stockholders' Equity Note [Abstract]

Summary of weighted-average assumptions used to estimate the fair values of the stock options granted

The weighted-average assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:

		Enochian Biosciences Inc.
Expected term (in years)		5.5
Volatility		79.92%-80.03%
Risk free interest rate		0.26%-.34%
Dividend yield		0%

Summary of stock options outstanding

A summary of the status of the Plan Options and Grant Warrants outstanding at September 30, 2020 is presented below:

Options Outstanding							Options Exercisable
	Exercise Prices		Number Outstanding		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price
	$	2.69		55,762		9.44	$	2.69		—		—	$	—
	$	3.26		23,006		9.42	$	3.26		—		—	$	—
	$	3.84		11,719		9.84	$	3.84		—		—	$	—
	$	3.85		5,195		9.84	$	3.85		—		—	$	—
	$	3.95		5,063		7.84	$	3.95		5,063		7.84	$	3.95
	$	4.12		7,282		9.80	$	4.12		—		—	$	—
	$	4.63		10,000		8.90	$	4.63		10,000		8.90	$	4.63
	$	4.80		50,749		9.25	$	4.80		—		—	$	—
	$	4.85		4,124		8.90	$	5.00		4,124		8.90	$	5.00
	$	4.90		9,183		8.86	$	4.90		9,183		8.86	$	4.90
	$	5.00		6,000		8.90	$	5.00		6000		—	$	5.00
	$	5.74		15,679		7.97	$	5.74		15,679		7.97	$	5.74
	$	5.80		7,759		8.03	$	5.80		7,759		8.03	$	5.80
	$	6.15		60,000		8.69	$	6.15		20,000		8.69	$	6.15
	$	6.25		24,001		8.44	$	6.25		24,001		8.44	$	6.25
	$	6.50		300,000		8.15	$	6.50		300,000		8.15	$	6.50
	$	6.95		4,317		8.53	$	6.95		4,317		8.53	$	6.95
	$	7.10		10,563		8.42	$	7.10		10,563		8.42	$	7.10
	$	8.00		519,235		9.42	$	8.00		55,695		7.60	$	8.00
Total	$	—		1,129,638		8.96	$	6.72		472,385		8.17	$	6.50

Summary of stock option activity

A summary of the status of the Plan Options at September 30, 2020 and changes since July 1, 2020 are presented below:

			Weighted Average		Average		Weighted Average
	Shares		Exercise Price		Remaining Life		Intrinsic Value

Outstanding at beginning of period		1,105,442	$	6.78		9.19	$	107,931
Granted		24,196	$	3.93		10.0		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
Outstanding at end of period		1,129,638	$	6.72		8.96	$	56,990
Vested and expected to vest								-
Exercisable end of period		472,385	$	6.50		8.17	$	-

Summary of common stock purchase warrants outstanding

A summary of the shares of Common Stock, which can be purchased related to the underlying the warrants outstanding for the three-month period as of September 30, 2020, is presented below:

			Weighted Average		Weighted Average
	Shares		Exercise Price		Remaining Life

Outstanding at beginning of period		1,438,122	$	1.42		1.74
Granted
Exercised		-		-		-
Cancelled/Expired		-		-		-
Outstanding at end of period		1,438,122	$	1.42		1.74
Exercisable end of period		1,438,122	$	1.42		1.74

Summary of common stock purchase warrants

		Equivalent Shares		Underlying Warrants		Outstanding		Equivalent Shares Exercisable
Exercise Prices		Equivalent Shares		Weight Average Remaining Contractual Life (years)		Weight Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	1.30		1,413,122		1.76	$	1.30		1,413,122	$	1.30
$	8.00		25,000		.37	$	8.00		25,000	$	8.00

Total			1,438,122		1.74	$	1.42		1,438,122	$	1.42

Summary of restricted stock units outstanding

A summary of the status of Restricted Stock Units outstanding at September 30, 2020 is presented below:

			Weighted Average		Weighted Average		Weighted Average
	Shares		Issuance Price		Remaining Life		Intrinsic Value

Outstanding at beginning of period		10,000	$	6.15		.77	$	—
Granted			$				$	—
Exercised			$
Cancelled/Expired			$				$	—
Outstanding at end of period		10,000	$	6.15		.77	$	—
Exercisable end of period		—	$	—		—	$	—

Summary of restricted stock units activity

		Restricted Stock Units Outstanding
Grant Price		Stock Units		Weight Average Remaining Contractual Life (years)		Weight Average Issuance Price
	6.15		10,000		.77	$	6.15
Total			10,000		.77	$	6.15

XML 35 R24.htm IDEA: XBRL DOCUMENT

THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Cash held in financial institutions	$ 5,965,661		$ 8,696,361
Goodwill	11,640,000		$ 11,640,000
Research and development expense	$ 1,050,376	$ 520,192
Common stock, par value	$ 0.0001		$ 0.0001
Anti-dilutive securities excluded from computation od EPS	4,115,883	3,441,375
Stock based compensation expense	$ 326,156	$ 234,010
General and Administrative Expense [Member]
Consulting Expenses		$ 31,850

XML 36 R25.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENT (Details)	3 Months Ended
FAIR VALUE MEASUREMENT (Details)	Sep. 30, 2020 USD ($)
Accounting Policies [Abstract]
Balance at beginning	$ 3,182,434
Contingent Shares issued pursuant to the Acquisition Agreement
Fair value adjustment	(427,400)
Balance at end	$ 2,755,034

XML 37 R26.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENT (Details Narrative) - USD ($)		3 Months Ended
FAIR VALUE MEASUREMENT (Details Narrative) - USD ($)	Feb. 16, 2018	Sep. 30, 2020	Jun. 30, 2020
Contingent consideration liability		$ 2,755,034	$ 3,182,434
Acquisition of Enochian Biopharma [Member]
Stock price		$ 3.58
Exercise price of warrants		$ 1.30
Risk-free rate		0.13%
Expected volatility		99.30%
Digital call rate		54.00%
Outstanding contingent shares		1,438,122
Agreement and Plan of Merger (the "Acquisition Agreement") [Member] \| Enochian Biopharma Inc. and Weird Science LLC [Member]
Shares issued on business combination	18,081,962	1,438,122
Contingent consideration liability	$ 21,516,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details) - USD ($)	3 Months Ended
PROPERTY AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Property, Plant and Equipment [Line Items]
Total	$ 931,131	$ 931,131
Less Accumulated Depreciation	(179,558)	(153,013)
PROPERTY AND EQUIPMENT, Net accumulated Depreciation	751,573	778,118
Lab equipment and instruments [Member]
Property, Plant and Equipment [Line Items]
Total	$ 534,527	534,527
Lab equipment and instruments [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Lab equipment and instruments [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Life	10 years
Total	$ 224,629	224,629
Furniture fixtures and equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$ 171,975	$ 171,975
Furniture fixtures and equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Furniture fixtures and equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years

XML 39 R28.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 26,545	$ 21,481

XML 40 R29.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details) - USD ($)	3 Months Ended
INTANGIBLE ASSETS (Details) - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Definite-life intangible assets	$ 76,834	$ 77,323
Period Change	(3,913)
Effect of Currency Translation	3,424
Indefinite Life Intangible Assets	166,464,000	166,464,000
Accumulated Amortization [Member]
Accumulated Amortization	(235,588)	(221,852)
Period Change	(3,913)
Effect of Currency Translation	$ (9,823)
Patents [Member]
Useful Life	20 years
Definite-life intangible assets	$ 312,422	299,175
Period Change	0
Effect of Currency Translation	13,247
Licensing Agreements [Member]
Indefinite Life Intangible Assets	154,824,000	154,824,000
Goodwill [Member]
Indefinite Life Intangible Assets	$ 11,640,000	$ 11,640,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details 1) - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Schedule of expected future amortization expense
2021	$ 11,241
2022	15,154
2023	15,154
2024	15,154
2025	15,154
Thereafter	4,977
Definite-life intangible assets, net	$ 76,834	$ 77,323

XML 42 R31.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended
INTANGIBLE ASSETS (Details Narrative) - USD ($)	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Definite-life intangible assets	$ 76,834		$ 77,323
Patents [Member]
Definite-life intangible assets	312,422		$ 299,175
Amortization expense	$ 3,913	$ 0

XML 43 R32.htm IDEA: XBRL DOCUMENT

LEASES (Details)	Sep. 30, 2020 USD ($)
Leases [Abstract]
2021	$ 255,137
2022	348,495
2023	298,305
2024	246,004
2025	253,384
Thereafter	574,821
Less imputed interest	(238,535)
Total	$ 1,737,611

XML 44 R33.htm IDEA: XBRL DOCUMENT

LEASES (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
LEASES (Details Narrative) - USD ($)	Nov. 13, 2017	Jun. 19, 2018	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Lease premises, description	On November 13, 2017, Enochian entered into a Lease Agreement for a term of five years and two months from November 1, 2017 (the "Term") with Plaza Medical Office Building, LLC, a California limited liability company (the "Landlord"), as landlord, pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increases by 3% each year, and ranges from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The Company received $70,800 in tenant improvement allowance in the form of free rent applied over 10 months in equal installments beginning in January of 2018.	On June 19, 2018, the Registrant entered into a Lease Agreement for a term of ten years from September 1, 2018 with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Registrant entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the remainder of the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050. The Company was entitled to $148,168 in contributions toward tenant improvements.
Weighted-average remaining term			6 years 2 months 27 days
Weighted-average discount rate			3.99%
Lease expense			$ 89,684	$ 101,521

XML 45 R34.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)	3 Months Ended		7 Months Ended	9 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Sep. 30, 2020	Sep. 30, 2019	Feb. 06, 2020	Mar. 30, 2020	Jun. 30, 2020
Accrued interest	$ 273,345				$ 470,636
Amortization of the discount	73,978
Convertible Notes Payable [Member]
Principal amount			$ 600,000
Issuance Date			Feb. 06, 2020
Maturity Date			Feb. 06, 2023
Interest rate			6.00%
Conversion price			$ 12.00
Convertible notes payable	1,200,000				$ 1,200,000
Note Payable [Member]
Principal amount				$ 5,000,000
Issuance Date				Mar. 30, 2020
Maturity Date				Nov. 30, 2021
Interest rate				6.00%
Stock issued for debt conversion, shares				188,485
Stock issued for debt conversion				$ 501,370
Proceeds received from issuance of shares				$ 493,192
Notes payable	4,654,765
Accrued interest	6,000
Interest expense	92,313
Amortization of the discount	$ 73,978

XML 46 R35.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details) - Enochian Biosciences [Member]	3 Months Ended
	Sep. 30, 2020
Expected term (in years)	5 years 6 months
Dividend yield	0.00%
Minimum [Member]
Volatility	79.92%
Risk free interest rate	0.26%
Maximum [Member]
Volatility	80.03%
Risk free interest rate	0.34%

XML 47 R36.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 1) - Employee Stock Option [Member] - $ / shares	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices
Options Outstanding, Number Outstanding	1,129,638	1,105,442
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 11 months 15 days
Options Outstanding, Weighted Average Exercise Price	$ 6.72	$ 6.78
Options Exercisable, Number Exercisable	472,385
Options Exercisable, Weighted Average Remaining Contractual Life (years)	8 years 2 months 1 day
Options Exercisable, Weighted Average Exercise Price	$ 6.50
Exercise Price Range 2.69 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 2.69
Options Outstanding, Number Outstanding	55,762
Options Outstanding, Weighted Average Remaining Contractual Life (years)	9 years 5 months 9 days
Options Outstanding, Weighted Average Exercise Price	$ 2.69
Options Exercisable, Number Exercisable
Options Exercisable, Weighted Average Exercise Price
Exercise Price Range 3.26 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 3.26
Options Outstanding, Number Outstanding	23,006
Options Outstanding, Weighted Average Remaining Contractual Life (years)	9 years 5 months 1 day
Options Outstanding, Weighted Average Exercise Price	$ 3.26
Options Exercisable, Number Exercisable
Options Exercisable, Weighted Average Exercise Price
Exercise Price Range 3.84 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 3.84
Options Outstanding, Number Outstanding	11,719
Options Outstanding, Weighted Average Remaining Contractual Life (years)	9 years 10 months 3 days
Options Outstanding, Weighted Average Exercise Price	$ 3.84
Options Exercisable, Number Exercisable
Options Exercisable, Weighted Average Exercise Price
Exercise Price Range 3.85 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 3.85
Options Outstanding, Number Outstanding	5,195
Options Outstanding, Weighted Average Remaining Contractual Life (years)	9 years 10 months 3 days
Options Outstanding, Weighted Average Exercise Price	$ 3.85
Options Exercisable, Number Exercisable
Options Exercisable, Weighted Average Exercise Price
Exercise Price Range 3.95 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 3.95
Options Outstanding, Number Outstanding	5,063
Options Outstanding, Weighted Average Remaining Contractual Life (years)	7 years 10 months 3 days
Options Outstanding, Weighted Average Exercise Price	$ 3.95
Options Exercisable, Number Exercisable	5,063
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 10 months 3 days
Options Exercisable, Weighted Average Exercise Price	$ 3.95
Exercise Price Range 4.12 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 4.12
Options Outstanding, Number Outstanding	7,282
Options Outstanding, Weighted Average Remaining Contractual Life (years)	9 years 9 months 18 days
Options Outstanding, Weighted Average Exercise Price	$ 4.12
Options Exercisable, Number Exercisable
Options Exercisable, Weighted Average Exercise Price
Exercise Price Range 4.63 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 4.63
Options Outstanding, Number Outstanding	10,000
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 10 months 25 days
Options Outstanding, Weighted Average Exercise Price	$ 4.63
Options Exercisable, Number Exercisable	10,000
Options Exercisable, Weighted Average Remaining Contractual Life (years)	8 years 10 months 25 days
Options Exercisable, Weighted Average Exercise Price	$ 4.63
Exercise Price Range 4.80 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 4.8
Options Outstanding, Number Outstanding	50,749
Options Outstanding, Weighted Average Remaining Contractual Life (years)	9 years 2 months 30 days
Options Outstanding, Weighted Average Exercise Price	$ 4.8
Options Exercisable, Number Exercisable
Options Exercisable, Weighted Average Exercise Price
Exercise Price Range 4.85 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 4.85
Options Outstanding, Number Outstanding	4,124
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 10 months 25 days
Options Outstanding, Weighted Average Exercise Price	$ 5
Options Exercisable, Number Exercisable	4,124
Options Exercisable, Weighted Average Remaining Contractual Life (years)	8 years 10 months 25 days
Options Exercisable, Weighted Average Exercise Price	$ 5
Exercise Price Range 4.90 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 4.9
Options Outstanding, Number Outstanding	9,183
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 10 months 10 days
Options Outstanding, Weighted Average Exercise Price	$ 4.9
Options Exercisable, Number Exercisable	9,183
Options Exercisable, Weighted Average Remaining Contractual Life (years)	8 years 10 months 10 days
Options Exercisable, Weighted Average Exercise Price	$ 4.9
Exercise Price Range 5.00 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 5
Options Outstanding, Number Outstanding	6,000
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 10 months 25 days
Options Outstanding, Weighted Average Exercise Price	$ 5
Options Exercisable, Number Exercisable	6,000
Options Exercisable, Weighted Average Exercise Price	$ 5
Exercise Price Range 5.74 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 5.74
Options Outstanding, Number Outstanding	15,679
Options Outstanding, Weighted Average Remaining Contractual Life (years)	7 years 11 months 19 days
Options Outstanding, Weighted Average Exercise Price	$ 5.74
Options Exercisable, Number Exercisable	15,679
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 11 months 19 days
Options Exercisable, Weighted Average Exercise Price	$ 5.74
Exercise Price Range 5.80 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 5.8
Options Outstanding, Number Outstanding	7,759
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 11 days
Options Outstanding, Weighted Average Exercise Price	$ 5.8
Options Exercisable, Number Exercisable	7,759
Options Exercisable, Weighted Average Remaining Contractual Life (years)	8 years 11 days
Options Exercisable, Weighted Average Exercise Price	$ 5.8
Exercise Price Range 6.15 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 6.15
Options Outstanding, Number Outstanding	60,000
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 8 months 9 days
Options Outstanding, Weighted Average Exercise Price	$ 6.15
Options Exercisable, Number Exercisable	20,000
Options Exercisable, Weighted Average Remaining Contractual Life (years)	8 years 8 months 9 days
Options Exercisable, Weighted Average Exercise Price	$ 6.15
Exercise Price Range 6.25 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 6.25
Options Outstanding, Number Outstanding	24,001
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 5 months 9 days
Options Outstanding, Weighted Average Exercise Price	$ 6.25
Options Exercisable, Number Exercisable	24,001
Options Exercisable, Weighted Average Remaining Contractual Life (years)	8 years 5 months 9 days
Options Exercisable, Weighted Average Exercise Price	$ 6.25
Exercise Price Range 6.50 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 6.5
Options Outstanding, Number Outstanding	300,000
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 1 month 24 days
Options Outstanding, Weighted Average Exercise Price	$ 6.5
Options Exercisable, Number Exercisable	300,000
Options Exercisable, Weighted Average Remaining Contractual Life (years)	8 years 1 month 24 days
Options Exercisable, Weighted Average Exercise Price	$ 6.5
Exercise Price Range 6.95 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 6.95
Options Outstanding, Number Outstanding	4,317
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 6 months 10 days
Options Outstanding, Weighted Average Exercise Price	$ 6.95
Options Exercisable, Number Exercisable	4,317
Options Exercisable, Weighted Average Remaining Contractual Life (years)	8 years 6 months 10 days
Options Exercisable, Weighted Average Exercise Price	$ 6.95
Exercise Price Range 7.10 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 7.1
Options Outstanding, Number Outstanding	10,563
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 5 months 1 day
Options Outstanding, Weighted Average Exercise Price	$ 7.1
Options Exercisable, Number Exercisable	10,563
Options Exercisable, Weighted Average Remaining Contractual Life (years)	8 years 5 months 1 day
Options Exercisable, Weighted Average Exercise Price	$ 7.1
Exercise Price Range 8.00 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 8
Options Outstanding, Number Outstanding	519,235
Options Outstanding, Weighted Average Remaining Contractual Life (years)	9 years 5 months 1 day
Options Outstanding, Weighted Average Exercise Price	$ 8
Options Exercisable, Number Exercisable	55,695
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 7 months 6 days
Options Exercisable, Weighted Average Exercise Price	$ 8

XML 48 R37.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 2) - Employee Stock Option [Member]	3 Months Ended
	Sep. 30, 2020 USD ($) $ / shares shares
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding at beginning of period \| shares	1,105,442
Options Outstanding, Granted \| shares	24,196
Options Outstanding, Exercised \| shares
Options Outstanding, Forfeited \| shares
Options Outstanding, Expired \| shares
Options Outstanding at end of period \| shares	1,129,638
Vested and expected to vest \| shares
Options Exercisable, Number Exercisable \| shares	472,385
Weighted Average Exercise Price, Outstanding at beginning of period \| $ / shares	$ 6.78
Weighted Average Exercise Price, Granted \| $ / shares	3.93
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Forfeited \| $ / shares
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Outstanding at end of period \| $ / shares	6.72
Weighted Average Exercise Price, Vested and expected to vest \| $ / shares
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 6.50
Weighted Average remaining life, Outstanding at beginning of period	9 years 2 months 8 days
Weighted Average remaining life, Granted	10 years
Weighted Average remaining life, Outstanding at end of period	8 years 11 months 15 days
Weighted Average Remaining Life, Exercisable end of period	8 years 2 months 1 day
Weighted Average Intrinsic Value, Outstanding at beginning of period \| $	$ 107,931
Weighted Average Intrinsic Value, Granted \| $
Weighted Average Intrinsic Value, Exercised \| $
Weighted average intrinsic value, Forfeited \| $
Weighted average intrinsic value, Expired \| $
Weighted Average Intrinsic Value, Outstanding at end of period \| $	56,990
Weighted Average Intrinsic Value, Vested and expected to vest \| $
Weighted Average Intrinsic Value, Exercisable end of period \| $

XML 49 R38.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 3) - Common Stock Purchase Warrants [Member] - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2020	Jun. 30, 2020
Option Indexed to Issuer's Equity [Line Items]
Outstanding at beginning of period	1,438,122
Granted
Exercised
Cancelled/Expired
Outstanding at end of period	1,438,122	1,438,122
Exercisable end of period	1,438,122
Weighted average exercise price, Outstanding at beginning of period	$ 1.42
Weighted average exercise price, Exercised
Weighted average exercise price, Expired
Weighted average exercise price, Outstanding at end of period	1.42	$ 1.42
Weighted average exercise price, Exercisable end of period	$ 1.42
Weighted Average remaining life, Outstanding	1 year 8 months 26 days	1 year 8 months 26 days
Weighted Average remaining life, Exercisable end of period	1 year 8 months 26 days

XML 50 R39.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 4) - Warrant [Member]	3 Months Ended
STOCKHOLDERS' EQUITY (Details 4) - Warrant [Member]	Sep. 30, 2020 $ / shares shares
Option Indexed to Issuer's Equity [Line Items]
Equivalent Shares Underlying Warrants Outstanding, Equivalent Shares \| shares	1,438,122
Equivalent Shares Underlying Warrants Outstanding, Weighted Average Remaining Contractual Life (years)	1 year 8 months 26 days
Equivalent Shares Underlying Warrants Outstanding, Weighted Average Exercise Price	$ 1.42
Equivalent Shares Exercisable, Number Exercisable \| shares	1,438,122
Equivalent Shares Exercisable, Weighted Average Exercise Price	$ 1.42
Exercise Price Range 1.30 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 1.30
Equivalent Shares Underlying Warrants Outstanding, Equivalent Shares \| shares	1,413,122
Equivalent Shares Underlying Warrants Outstanding, Weighted Average Remaining Contractual Life (years)	1 year 9 months 3 days
Equivalent Shares Underlying Warrants Outstanding, Weighted Average Exercise Price	$ 1.30
Equivalent Shares Exercisable, Number Exercisable \| shares	1,413,122
Equivalent Shares Exercisable, Weighted Average Exercise Price	$ 1.30
Exercise Price Range 8.00 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 8.00
Equivalent Shares Underlying Warrants Outstanding, Equivalent Shares \| shares	25,000
Equivalent Shares Underlying Warrants Outstanding, Weighted Average Remaining Contractual Life (years)	4 months 13 days
Equivalent Shares Underlying Warrants Outstanding, Weighted Average Exercise Price	$ 8.00
Equivalent Shares Exercisable, Number Exercisable \| shares	25,000
Equivalent Shares Exercisable, Weighted Average Exercise Price	$ 8.00

XML 51 R40.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 5) - Employee Stock Option [Member]	3 Months Ended
	Sep. 30, 2020 USD ($) $ / shares shares
Outstanding at beginning of period	10,000
Granted
Exercised
Cancelled/Expired
Outstanding at end of period	10,000
Exercisable end of period
Weighted average Issuance price, Outstanding at beginning of period \| $ / shares	$ 6.15
Weighted average Issuance price, Granted \| $ / shares
Weighted average Issuance price, Exercised \| $ / shares
Weighted average Issuance price, Expired \| $ / shares
Weighted average Issuance price, Outstanding at end of period \| $ / shares	$ 6.15
Weighted average Issuance price, Exercisable end of period
Weighted Average remaining life, Outstanding	9 months 7 days
Weighted Average remaining life, Exercisable end of period	9 months 7 days
Weighted Average Intrinsic Value, Outstanding at end of period \| $
Weighted average Intrinsic Value, Exercisable end of period \| $

XML 52 R41.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 6) - Employee Stock Option [Member] - $ / shares	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020
Stock Units	10,000	10,000
Weighted Average remaining life, Outstanding	9 months 7 days
Weight Average Issuance Price	$ 6.15
Exercise Price Range 6.15 [Member]
Grant Price	$ 6.15
Stock Units	10,000
Weighted Average remaining life, Outstanding	9 months 7 days
Weight Average Issuance Price	$ 6.15

XML 53 R42.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)					3 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Jul. 08, 2020	Jul. 03, 2019	Feb. 16, 2018	Feb. 06, 2014	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Class of Stock [Line Items]
Preferred stock, par value					$ 0.0001		$ 0.0001
Preferred stock, shares authorized					10,000,000		10,000,000
Preferred stock, shares issued					0		0
Preferred stock, shares outstanding					0		0
Common stock, shares authorized					100,000,000		100,000,000
Common stock, par value					$ 0.0001		$ 0.0001
Common stock, shares issued					46,636,976		46,497,409
Common stock, shares outstanding					46,636,976		46,497,409
Shares issued for business acquisition, value						$ 2,210,000
Common stock reserved for issuance					77,249		82,237
Share exchange agreement, shares issued to parent company					24,196
Stock based compensation expense					$ 316,950	226,266
Unrecognized compensation cost related to non-vested options							$ 836,754
Vested warrants shares					1,438,122
Common stock issued					4,988
Stock Option [Member]
Class of Stock [Line Items]
Shares issued for options exercised		500,000
Shares price		$ 2.00
Proceeds from stock option exercised		$ 1,000,000
Employee Stock Option [Member]
Class of Stock [Line Items]
Shares issued for options exercised
Options granted and outstanding
Stock based compensation expense					$ 9,206	$ 7,744
Board of Directors [Member]
Class of Stock [Line Items]
Options granted and outstanding						13,470
Senior Employees [Member]
Class of Stock [Line Items]
Options granted and outstanding						20,000
DanDrit Denmark [Member]
Class of Stock [Line Items]
Common stock, shares issued					107,804
2014 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Common stock reserved for issuance				1,206,000
2019 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Options granted and outstanding					1,129,638
Plan option description				Board approved and on October 31, 2019, the Company’s shareholders adopted the Enochian’s 2019 Equity Incentive Plan (the “2019 Plan”), which replaced the 2014 Plan. The 2019 Plan authorized options to be awarded to not exceed the sum of (1) 6,000,000 new shares of Common Stock, and (2) the number of shares of Common Stock available for the grant of awards as of the effective date under the 2014 Plan that, after the effective date of the 2019 Plan, expires, or is terminated, surrendered, or forfeited for any reason without issuance of shares. The remaining shares of Common Stock available for grant related to the 2014 Plan was of 655,769 as of the effective date, this amount along with the new 6,000,000 shares totals 6,655,769 shares of Common Stock available to grant immediately after the effective date of the 2019 Plan.
Employee Stock Option [Member]
Class of Stock [Line Items]
Shares issued for options exercised
Options granted and outstanding					24,196
Option Exercisable					472,385
Intrinsic value of stock option					$ 0
Enochian Biosciences [Member]
Class of Stock [Line Items]
Shares issued for business acquisition, shares		500,000
Shares issued price per share		$ 4.42
Shares issued for business acquisition, value		$ 2,200,000
Agreement and Plan of Merger (the "Acquisition Agreement") [Member] \| Enochian Biopharma Inc. and Weird Science LLC [Member]
Class of Stock [Line Items]
Shares issued on business combination			18,081,962		1,438,122
Lincoln Park [Member] \| Purchase Agreement [Member]
Class of Stock [Line Items]
Maximum limit of shares reserved for sale	$ 20,000,000
Purchase agreement, description	Under the Purchase Agreement, we may direct Lincoln Park, at our sole discretion subject to certain conditions, to purchase up to 200,000 shares of Common Stock on any business day (a “Regular Purchase”). The amount of a Regular Purchase may be increased under certain circumstances up to 125,000 shares of Common Stock, provided that Lincoln Park’s committed obligation for Regular Purchases on any business day shall not exceed $1,000,000
Shares issued for commitment fee	139,567

XML 54 R43.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended
	Feb. 06, 2020	Jul. 09, 2018	Jan. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Research and development expenses				$ 1,050,376	$ 520,192
Common stock reserved for issuance				77,249		82,237
Common stock issued				4,988
G-Tech[Member] \| License Agreement
Royalty Percentage			2.00%
Payment for license	$ 1,200,000
Consulting Agreement [Member] \| G-Tech[Member]
Consulting expenses		$ 130,000
Monthly consulting fee				$ 25,000
Research and development expenses				50,000	$ 375,000
Monthly research costs				144,500
Payment for scientific staffing resources				433,500
Payment for materials				$ 400,000

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 144 337 1 false 57 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://enochianbio.com/role/Documentandentityinformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://enochianbio.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://enochianbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://enochianbio.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS (UNAUDITED) Sheet http://enochianbio.com/role/ConsolidatedStatementsOfOtherComprehensiveLoss CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS (UNAUDITED) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Sheet http://enochianbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://enochianbio.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 7 false false R8.htm 00000008 - Disclosure - THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://enochianbio.com/role/SummaryOfSignificantAccountingPolicies THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - FAIR VALUE MEASUREMENT Sheet http://enochianbio.com/role/FairValueMeasurement FAIR VALUE MEASUREMENT Notes 9 false false R10.htm 00000010 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://enochianbio.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 10 false false R11.htm 00000011 - Disclosure - INTANGIBLE ASSETS Sheet http://enochianbio.com/role/Definite-lifeIntangibleAssets INTANGIBLE ASSETS Notes 11 false false R12.htm 00000012 - Disclosure - LEASES Sheet http://enochianbio.com/role/Leases LEASES Notes 12 false false R13.htm 00000013 - Disclosure - NOTES PAYABLE Notes http://enochianbio.com/role/NotesPayable NOTES PAYABLE Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://enochianbio.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://enochianbio.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 00000016 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://enochianbio.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://enochianbio.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://enochianbio.com/role/BusinessAndSummaryOfSignificantAccountingPoliciesPolicies THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - FAIR VALUE MEASUREMENT (Tables) Sheet http://enochianbio.com/role/BusinessAndSummaryOfSignificantAccountingPoliciesTables FAIR VALUE MEASUREMENT (Tables) Tables http://enochianbio.com/role/FairValueMeasurement 19 false false R20.htm 00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://enochianbio.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://enochianbio.com/role/PropertyAndEquipment 20 false false R21.htm 00000021 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://enochianbio.com/role/Definite-lifeIntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://enochianbio.com/role/Definite-lifeIntangibleAssets 21 false false R22.htm 00000022 - Disclosure - LEASES (Tables) Sheet http://enochianbio.com/role/LeasesTables LEASES (Tables) Tables http://enochianbio.com/role/Leases 22 false false R23.htm 00000023 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://enochianbio.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://enochianbio.com/role/StockholdersEquity 23 false false R24.htm 00000024 - Disclosure - THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://enochianbio.com/role/BusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://enochianbio.com/role/BusinessAndSummaryOfSignificantAccountingPoliciesPolicies 24 false false R25.htm 00000025 - Disclosure - FAIR VALUE MEASUREMENT (Details) Sheet http://enochianbio.com/role/BusinessAndSummaryOfSignificantAccountingPoliciesDetails1 FAIR VALUE MEASUREMENT (Details) Details http://enochianbio.com/role/BusinessAndSummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative) Sheet http://enochianbio.com/role/FairValueMeasurementDetailsNarrative FAIR VALUE MEASUREMENT (Details Narrative) Details http://enochianbio.com/role/BusinessAndSummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://enochianbio.com/role/PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://enochianbio.com/role/PropertyAndEquipmentTables 27 false false R28.htm 00000028 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://enochianbio.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://enochianbio.com/role/PropertyAndEquipmentTables 28 false false R29.htm 00000029 - Disclosure - INTANGIBLE ASSETS (Details) Sheet http://enochianbio.com/role/Definite-lifeIntangibleAssetsDetails INTANGIBLE ASSETS (Details) Details http://enochianbio.com/role/Definite-lifeIntangibleAssetsTables 29 false false R30.htm 00000030 - Disclosure - INTANGIBLE ASSETS (Details 1) Sheet http://enochianbio.com/role/Definite-lifeIntangibleAssetsDetails1 INTANGIBLE ASSETS (Details 1) Details http://enochianbio.com/role/Definite-lifeIntangibleAssetsTables 30 false false R31.htm 00000031 - Disclosure - INTANGIBLE ASSETS (Details Narrative) Sheet http://enochianbio.com/role/IntangibleAssetsDetailsNarrative INTANGIBLE ASSETS (Details Narrative) Details http://enochianbio.com/role/Definite-lifeIntangibleAssetsTables 31 false false R32.htm 00000032 - Disclosure - LEASES (Details) Sheet http://enochianbio.com/role/LeasesDetails LEASES (Details) Details http://enochianbio.com/role/LeasesTables 32 false false R33.htm 00000033 - Disclosure - LEASES (Details Narrative) Sheet http://enochianbio.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://enochianbio.com/role/LeasesTables 33 false false R34.htm 00000034 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://enochianbio.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://enochianbio.com/role/NotesPayable 34 false false R35.htm 00000035 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://enochianbio.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://enochianbio.com/role/StockholdersEquityTables 35 false false R36.htm 00000036 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) Sheet http://enochianbio.com/role/StockholdersEquityDetails1 STOCKHOLDERS' EQUITY (Details 1) Details http://enochianbio.com/role/StockholdersEquityTables 36 false false R37.htm 00000037 - Disclosure - STOCKHOLDERS' EQUITY (Details 2) Sheet http://enochianbio.com/role/StockholdersEquityDetails2 STOCKHOLDERS' EQUITY (Details 2) Details http://enochianbio.com/role/StockholdersEquityTables 37 false false R38.htm 00000038 - Disclosure - STOCKHOLDERS' EQUITY (Details 3) Sheet http://enochianbio.com/role/StockholdersEquityDetails3 STOCKHOLDERS' EQUITY (Details 3) Details http://enochianbio.com/role/StockholdersEquityTables 38 false false R39.htm 00000039 - Disclosure - STOCKHOLDERS' EQUITY (Details 4) Sheet http://enochianbio.com/role/StockholdersEquityDetails4 STOCKHOLDERS' EQUITY (Details 4) Details http://enochianbio.com/role/StockholdersEquityTables 39 false false R40.htm 00000040 - Disclosure - STOCKHOLDERS' EQUITY (Details 5) Sheet http://enochianbio.com/role/StockholdersEquityDetails5 STOCKHOLDERS' EQUITY (Details 5) Details http://enochianbio.com/role/StockholdersEquityTables 40 false false R41.htm 00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details 6) Sheet http://enochianbio.com/role/StockholdersEquityDetails6 STOCKHOLDERS' EQUITY (Details 6) Details http://enochianbio.com/role/StockholdersEquityTables 41 false false R42.htm 00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://enochianbio.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://enochianbio.com/role/StockholdersEquityTables 42 false false R43.htm 00000043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://enochianbio.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://enochianbio.com/role/CommitmentsAndContingencies 43 false false All Reports Book All Reports enob-20200930.xml enob-20200930.xsd enob-20200930_cal.xml enob-20200930_def.xml enob-20200930_lab.xml enob-20200930_pre.xml http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 60 0001731122-20-001140-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001731122-20-001140-xbrl.zip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end

STOCKHOLDERS' EQUITY (Details 2) - Employee Stock Option [Member]	3 Months Ended
	Sep. 30, 2020 USD ($) $ / shares shares
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding at beginning of period \| shares	1,105,442
Options Outstanding, Granted \| shares	24,196
Options Outstanding, Exercised \| shares
Options Outstanding, Forfeited \| shares
Options Outstanding, Expired \| shares
Options Outstanding at end of period \| shares	1,129,638
Vested and expected to vest \| shares
Options Exercisable, Number Exercisable \| shares	472,385
Weighted Average Exercise Price, Outstanding at beginning of period \| $ / shares	$ 6.78
Weighted Average Exercise Price, Granted \| $ / shares	3.93
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Forfeited \| $ / shares
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Outstanding at end of period \| $ / shares	6.72
Weighted Average Exercise Price, Vested and expected to vest \| $ / shares
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 6.50
Weighted Average remaining life, Outstanding at beginning of period	9 years 2 months 8 days
Weighted Average remaining life, Granted	10 years
Weighted Average remaining life, Outstanding at end of period	8 years 11 months 15 days
Weighted Average Remaining Life, Exercisable end of period	8 years 2 months 1 day
Weighted Average Intrinsic Value, Outstanding at beginning of period \| $	$ 107,931
Weighted Average Intrinsic Value, Granted \| $
Weighted Average Intrinsic Value, Exercised \| $
Weighted average intrinsic value, Forfeited \| $
Weighted average intrinsic value, Expired \| $
Weighted Average Intrinsic Value, Outstanding at end of period \| $	56,990
Weighted Average Intrinsic Value, Vested and expected to vest \| $
Weighted Average Intrinsic Value, Exercisable end of period \| $